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1  GENERAL PART 
1.1 INTRODUCTION 
Poisonings with plants or plant ingredients as well as their abuse are widespread and 
play an important role in clinical and forensic toxicology. According to the annual report 
of 2005 of the poison information center of northern Germany, 12 % of the medicinal 
consultations and advice related to plants or plant ingredients (Fig. 1.1.). Although many 
plants contain pharmacologically active ingredients, severe poisonings with plants are 
relatively rare and limited to a few toxic plant species.1  
 
 
Fig. 1.1. Distribution of medical consultions of the Poison Information Center of Northern Germany 
 
Besides plant poisonings, a lot of these consultations concern the abuse of plants and 
plant ingredients. The main reasons of such an abuse are the wish to experience 
stimulative or hallucinogenic effects, to induce or support loosing weight, or simply 
habitual misuse. In contrast to classical drugs of abuse such as tetrahydrocannabinol 
(THC), opiates, cocaine, and amphetamines, the so-called “herbal” or “natural” drugs 
are often thought to be relatively harmless and propagated as "safe". For these reasons 
and because of a well-organized publicity in the internet, they have become increasingly 
popular among drug abusers in recent years. However, as in case of classical drugs of 
abuse, abuse of plants or plant ingredients may cause psychiatric problems like 
addiction or chronic illnesses. Depending on the pharmacological activity of the 
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contained active ingredients, they may even cause serious acute intoxications and 
poisonings, especially in overdose situations. In the following, an overview of herbal 
drugs leading to an abuse and/or intoxication is given.  
 
1.1.1 Laxatives 
The stimulant laxatives of the anthraquinone type (e.g. rhein) contained in plant extracts 
of cascara, senna, rhubarb, frangula, and aloe as well as of the diphenol-type 
phenolphthalein, bisacodyl, and sodium picosulfate are widely used and abused drugs. 
They are freely available over-the-counter drugs which are well tolerated for self 
medication and generally viewed as harmless, because their occasional use is 
associated with only few unwanted side effects.2 The chemical structures of the 
above-mentioned laxatives are given in Fig. 1.2. 
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Fig. 1.2. Chemical structures of bisacodyl, picosulfate, rhein, and pheolphthalein. 
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However, the above-mentioned drugs are also widely abused for various reasons. On 
the one hand, there are surreptitious laxative abusers, whose abuse is often associated 
with an eating disorder like bulimia nervosa or anorexia3-10 or with Munchhausen 
syndrome.11 In case of eating disorders, a study of Pryor et al. showed that more than 
50 % of patients had abused laxatives at some point.12 On the other hand, there are 
habitual abusers, which are usually middle-aged and start using these drugs for 
treatment of constipation due to poor diet, decreased mobility or concomitant drug 
therapy. Such a chronic use or abuse can induce hypokalemia, which in turn leads to 
constipation, thus leading to a vicious circle of laxative abuse and constipation. 
Laxative-induced hypokalemia may even lead to life threatening disorders like torsade 
de pointes.10 Other unwanted side effects of chronic laxative abuse are abdominal pain, 
chronic diarrhea, dehydration, disturbance of acid-base balance, and reversible or 
irreversible damages as well as inflammatory changes of the colonic mucosa.2,7,9,13-15 
Because of the heterogeneity of these side effects and their similarity to symptoms of 
gastrointestinal disorders, a toxicological screening for laxatives should be part of the 
differential diagnosis of such disorders.3,4 This may also help to avoid extensive and 
expensive diagnostic work. 
 
1.1.2 Nutmeg 
Nutmegs, the seeds of the evergreen tropical tree Myristica fragrans Houtt., are mainly 
used as a spice. They are described to be psychoactive when administered in high 
doses.16 Psychoactive properties were already described by Hildegard von Bingen in 
the Middle Ages.17 More recently, different psychotropic effects have been described in 
case reports after suspected intake of high doses of nutmegs.17-21 The main ingredients 
of the volative oil of nutmeg are the alkenebenzene derivatives elemicin (1-(3’,4’,5’-
trimethoxyphenyl)-prop-2-ene), myristicin (1-(3’,4’-methylenedioxy-5’-methoxyphenyl)-
prop-2-ene), and safrole (1-(3’,4’-methylenedioxyphenyl)-prop-2-ene).22 The structures 
of these ingredients are given in Fig. 1.3. 
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Fig. 1.3. Chemical structures of the main ingredients of the volative oil of nutmeg, safrole, myristicin, and 
elemicin 
 
In 1966, Shulgin hypothesized that the possible psychotropic effects of myristicin may 
be caused by metabolic addition of ammonia to the allyl side chain leading to the 
amphetamine derivative 3,4-methylenedioxy-5-methoxyamphetamine (MMDA)23 and 
that of elemicin by conversion to 3,4,5-trimethoxyamphetamine (TMA).24 These 
proposed metabolic steps are given in Fig. 1.4, but have not been proven so far. 
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Fig. 1.4. Postulated metabolic pathways of safrole, myristicin, and elemicin to 3,4-methylenedioxy-
amphetamine (MDA), 3,4-methylenedioxy-5-methoxy-amphetamine (MMDA), and 3,4,5-trimethoxy-
amphetamine (TMA). 
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1.1.3 Herbal Phenalkylamines 
Herbal drugs of Ephedra species have been abused as stimulants for centuries. 
Ephedra is a shrub-like evergreen plant found in arid regions of Europe, central Asia, 
and other parts of the world. Major species of Ephedra include Ephedra sinica Stapf., E. 
equisetina Bunge, E. intermedia, and E. distachya.25 The traditional Chinese medicine 
Ma Huang, derived from aerial parts of Ephedra, and has been used for the treatment of 
asthma, bronchial spasms, and as stimulant or diaphoretic.26  
 
NH2
OH
NH2
OH
N
H
OH
N
H
OH
N
OH
N
OH
N
H
OH
OH
Norephedrine Norpseudoephedrine 
Ephedrine Pseudoephedrine 
Methylephedrine Methylpseudoephedrine 
Synephrine  
 
Fig. 1.5. Chemical structures of norephedrine, norpseudoephedrine (cathine), ephedrine, 
pseudoephedrine, methylephedrine, methylpseudoephedrine, and synephrine. 
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The main pharmacologically active ingredients of Ephedra species are the alkaloids 
ephedrine and pseudoephedrine as well as norephedrine, norpseudoephedrine 
(cathine), methylephedrine, and methylpseudoephedrine.27-30 These compounds are 
potent central nervous system (CNS) stimulants and also have sympathomimetic effects 
in the peripheral nervous system. Ephedrine, norpseudoephedrine and methylephedrine 
were banned as doping agents by the International Olympic Committee. Because of the 
peripheral effects, ephedrine, pseudoephedrine, or norephedrine are often contained in 
cold medications. Norephedrine and norpseudoephedrine are often contained in 
anorectic medications. Such medicaments are often abused as well as supplements 
containing the anorectic compound synephrine (oxedrine).31,32 The chemical structures 
of all mentioned ephedrines and synephrine are depicted in Fig. 1.5. 
 
The psychostimulant herbal drug khat (Catha edulis Forsk.) is also abused. Khat is 
cultivated and abused mainly in East Africa and the Arab Peninsula. Emigrants from 
these countries try to maintain this habit, and large quantities of fresh khat are imported 
into other areas in the world. For example, >2300 kg of khat were confiscated at the 
Frankfurt airport (Germany) in 1998.33 The main alkaloids of khat are the 
psychostimulants cathinone, norpseudoephedrine and norephedrine.33-35 Cathinone is 
also a CNS stimulant and has sympathomimetic effects in the peripheral nervous 
system. Cathinone and norpseudoephedrine are controlled substances in many 
countries due to the khat abuse. A structurally related drug of relevance in this context 
is the synthetic designer drug methcathinone.36-42 The chemical structures of cathinone 
and methcathinone are depicted in Fig. 1.6. 
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Fig. 1.6. Chemical structures of cathinone and methcathinone. 
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Finally, one of the oldest known and best studied herbal drugs of abuse containing 
phenalkylamines is Lophophora williamsii Coult. (peyote). It contains the hallucinogenic 
alkaloid mescaline.43,44 Mescaline acts as partial agonist at 5-HT2A and other 5-HT2 
receptors in the central nervous system. The noradrenergic locus coeruleus and the 
cerebral cortex are among the regions where hallucinogens have prominent effects 
through their actions upon 5-HT2A receptors.44-48 The chemical structure of mescaline is 
depicted in Fig. 1.7. 
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Fig. 1.7. Chemical structure of mescaline. 
 
1.1.4 Toxic Alkaloids 
The most common herbal drug of abuse is Nicotiana tabacum L. A description of all the 
severe side effects of smoking is found in many handbooks. Intoxications do usually not 
occur after smoking of tobacco products, but may occur after oral ingestion of tobacco, 
e.g. by small children eating cigarettes. Nicotine acts by stimulation of the 
N-cholinoreceptors and is quickly metabolized to cotinine. The Strucures of nicotine and 
its metabolite cotinine are depicted in Fig. 1.8. 
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Fig. 1.8. Chemical structures of nicotine and cotinine. 
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Apart from the above-mentioned drugs of abuse, very popular herbal drugs abused for 
psychoactive reasons are plants of the nightshade family like Atropa belladonna L. 
(deadly nightshade), Datura stramonium L. (Jimson weed), or Datura arborea L. (angles 
trumpet). These plants contain as main active ingredients scopolamine and 
hyoscyamine which easily racemizes to atropine during storage, isolation and/or gastro-
intestinal passage. These substances are potent anticholinergic substances, blocking 
the M-subtypes of acetylcholine receptors.49,50 Due to the common abuse, these 
substances were banned in many countries. The structures of atropine and 
scopolamine are given in Fig. 1.9. 
 
O
O
N
OH
O
O
N
OH
O
Atropine Scopolamine 
 
 
Fig. 1.9. Chemical structures of atropine and scopolamine. 
 
Such plants may also cause severe or even fatal poisonings for example after 
unintentional ingestion. An unintentional ingestion of plants is most common among 
young children who often eat plants which seem attractive to them. Atropa belladonna 
L. is attractive for children due to its colorful and even sweet berries.  
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Another plant, attractive for children is Laburnum anagyroides L. with fruits similar to 
beans or peas. The plant contains the alkaloid Cytisine as main active compound. 
Cytisine acts like nicotine by stimulation of N-cholinoceptors and a resulting 
overstimulation as a blocking agent on the CNS.49,51 The chemical structure of cytisine 
is given in Fig. 1.10. 
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Fig. 1.10. Chemical structure of cytisine 
 
An unintentional or accidental ingestion can also be caused by mix-up of toxic plants 
with medicinal or nutritional plants. In Germany people often mix-up Colchicum 
autumnale L. containing colchicine with Allium ursinum known as Ramsons. Such 
accidental ingestion due to a mix-up is described in many case reports.52-59 Colchicum 
autumnale is a very toxic plant due to its main alkaloid colchicine. Colchicine acts via 
disruption of microtubules.49,51,60 The chemical structure of colchicine is given in Fig. 
1.11. 
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Fig. 1.11 Chemical structure of colchicine 
 
1.1 Introduction 9 
 
 
Another plant, attractive for children is Laburnum anagyroides L. with fruits similar to 
beans or peas. The plant contains the alkaloid Cytisine as main active compound. 
Cytisine acts like nicotine by stimulation of N-cholinoceptors and a resulting 
overstimulation as a blocking agent on the CNS.49,51 The chemical structure of cytisine 
is given in Fig. 1.10. 
 
N
NH
O
Cytisine  
 
Fig. 1.10. Chemical structure of cytisine 
 
An unintentional or accidental ingestion can also be caused by mix-up of toxic plants 
with medicinal or nutritional plants. In Germany people often mix-up Colchicum 
autumnale L. containing colchicine with Allium ursinum known as Ramsons. Such 
accidental ingestion due to a mix-up is described in many case reports.52-59 Colchicum 
autumnale is a very toxic plant due to its main alkaloid colchicine. Colchicine acts via 
disruption of microtubules.49,51,60 The chemical structure of colchicine is given in Fig. 
1.11. 
 
O
O
O O
O
N
H
O
Colchicine  
 
Fig. 1.11 Chemical structure of colchicine 
 
1.1 Introduction 9 
 
 
Another plant, attractive for children is Laburnum anagyroides L. with fruits similar to 
beans or peas. The plant contains the alkaloid Cytisine as main active compound. 
Cytisine acts like nicotine by stimulation of N-cholinoceptors and a resulting 
overstimulation as a blocking agent on the CNS.49,51 The chemical structure of cytisine 
is given in Fig. 1.10. 
 
N
NH
O
Cytisine  
 
Fig. 1.10. Chemical structure of cytisine 
 
An unintentional or accidental ingestion can also be caused by mix-up of toxic plants 
with medicinal or nutritional plants. In Germany people often mix-up Colchicum 
autumnale L. containing colchicine with Allium ursinum known as Ramsons. Such 
accidental ingestion due to a mix-up is described in many case reports.52-59 Colchicum 
autumnale is a very toxic plant due to its main alkaloid colchicine. Colchicine acts via 
disruption of microtubules.49,51,60 The chemical structure of colchicine is given in Fig. 
1.11. 
 
O
O
O O
O
N
H
O
Colchicine  
 
Fig. 1.11 Chemical structure of colchicine 
 
1.1 Introduction 9 
 
 
Another plant, attractive for children is Laburnum anagyroides L. with fruits similar to 
beans or peas. The plant contains the alkaloid Cytisine as main active compound. 
Cytisine acts like nicotine by stimulation of N-cholinoceptors and a resulting 
overstimulation as a blocking agent on the CNS.49,51 The chemical structure of cytisine 
is given in Fig. 1.10. 
 
N
NH
O
Cytisine  
 
Fig. 1.10. Chemical structure of cytisine 
 
An unintentional or accidental ingestion can also be caused by mix-up of toxic plants 
with medicinal or nutritional plants. In Germany people often mix-up Colchicum 
autumnale L. containing colchicine with Allium ursinum known as Ramsons. Such 
accidental ingestion due to a mix-up is described in many case reports.52-59 Colchicum 
autumnale is a very toxic plant due to its main alkaloid colchicine. Colchicine acts via 
disruption of microtubules.49,51,60 The chemical structure of colchicine is given in Fig. 
1.11. 
 
O
O
O O
O
N
H
O
Colchicine  
 
Fig. 1.11 Chemical structure of colchicine 
 
10 1 General Part 
 
 
Another plant sometimes mixed-up is Conium maculatum L. The seeds of Conium 
maculatum L. resembel those of anis or fennel. This plant is also mixed-up with the root 
of horseradish. Conium contains the alkaloid Coniine. The exact mechanism of action of 
coniine is not known.51 The chemical structure of coniine is given in Fig. 1.12. 
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Fig. 1.12. Chemical structure of coniine 
 
Sometimes, plants or their parts are also mixed up in alternative medicines. Aconitium 
napellus may be part of Chinese herbal medicines, and contains the alkaloid Aconitine. 
Intoxications are frequent after consumption of Aconitum, due to mix-up with other 
plants or wrong preparation. It has been suggested that aconitine acts as a potassium 
channel blocking agent. The complex chemical structure of aconitine is given in 
Fig. 1.13. 
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Fig. 1.13. Chemical structure of aconitine. 
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1.2 OVERVIEW OF PUBLISHED PROCEDURES AND AIMS FOR NEW STUDIES 
In the following, an overview is given on analytical methods published for the different 
studied herbal drugs. 
1.2.1 Laxatives 
Previously published procedures for screening for laxatives in urine samples used thin-
layer chromatography (TLC),61-64 high performance liquid chromatography (HPLC) with 
diode array65,66 or ultraviolet (UV)67 detection, or gas chromatography-mass 
spectrometry (GC-MS) after acetylation68 or trimethylsilylation.69 Part of these 
procedures61,63-66 allowed simultaneous screening for all the above-mentioned analytes, 
but required large volumes of urine,63,64 involved time consuming sample 
preparation,61,66 or lacked sensitivity,63,65 which limits their applicability in routine work. 
Therefore, there is still need for a comprehensive and sensitive screening procedure for 
simultaneous detection of an ingestion of diphenol- and anthraquinone-type laxatives in 
urine samples. The aim of the presented study was to adapt the previously published 
screening procedure for acidic drugs70-73 in urine for this purpose. This procedure 
employed GC-MS, the gold standard for toxicological screening analysis, after 
extractive methylation of urine samples. The target analytes for screening for laxatives 
were bisacodyl diphenol, the common metabolite of bisacodyl and sodium picosulfate, 
and phenolphthalein for the diphenol-type laxatives and rhein for the anthraquinone-
type laxatives.  
 
1.2.2 Nutmeg 
The main ingredients of the volative oil of nutmeg are the alkenebenzene derivatives 
elemicin, myristicin, and safrole.22 As already mentioned, Shulgin had hypothesized that 
the possible psychotropic effects of myristicin may be caused by metabolic addition of 
ammonia to the allyl side chain leading to the amphetamine derivative MMDA23 and that 
of elemicin by conversion to TMA.24 Years later, some authors reported the detection of 
MMDA in liver homogenisate after incubation with myristicin using TLC and 
fluorescence detection after dansylation.74,75 In case of safrole and myristicin, detection 
of different 3-amino-1-(3’,4’-methylenedioxyphenyl)-1-propanone derivatives in urine of 
rat and guinea pig was reported. TLC, mass spectrometry (MS), and nuclear magnetic 
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resonance spectroscopy (NMR) were used after sample treatment with sodium 
borohydride.76,77 However, in metabolism studies of the structurally related estragole (1-
(4’-methoxyphenyl)-prop-2-ene), the corresponding 4’-methoxyamphetamine (PMA) 
could not be detected by GC-MS.78  
In a case of suspected nutmeg abuse, urine samples submitted to our laboratory for 
toxicological analysis were analyzed using our systematic toxicological analysis (STA) 
procedure,79-84 but neither the above-mentioned amphetamine derivatives (detection 
limit 5-50 ng/ml85,86), nor the main nutmeg ingredients could be detected in urine, but a 
number of unknown mass spectra suspected to result from metabolites of the nutmeg 
ingredients. Urine screening for amphetamines by the Abbott TDx fluorescence 
polarization immunoassay amphetamine/methamphetamine II was negative (below the 
detection limit of 100 ng/ml). 
Therefore, the aim of the study here presented was to identify the metabolites of 
elemicin, myristicin, and safrole in rat urine and to confirm their presence in human 
urine of the nutmeg abuser using GC-MS in the electron ionization (EI) mode. In 
addition, the detectability of nutmeg ingredients and/or their metabolites within our STA 
procedure79-84 in urine by full-scan EI GC-MS will be described in order to confirm a 
nutmeg abuse or intoxication. 
 
1.2.3 Herbal Phenalkyamines 
In case of abuse or intoxication of herbal phenalkylamines, their detection and 
quantification in plasma is necessary in clinical and forensic toxicology.87 Furthermore, it 
can be important in the assessment of a probable abuse to differentiate an intake of 
Ephedra or  khat from an intake of corresponding cold or anorectic medications. Cold 
medications contain either ephedrine or its diastereomer pseudoephedrine and 
anorectics either norephedrine or its diastereomer norpseudoephedrine, while Ephedra 
species always contain all four diastereomers and additionally small amounts 
methylephedrine and methylpseudoephedrine. Hence, differentiation should be possible 
either by detection of methylephedrine or methylpseudoephedrine or by differentiation of 
the corresponding diastereomers ephedrine/pseudoephedrine or 
norephedrine/norpseudoephedrine. Differentiation of a khat or methcathinone abuse 
from intake of the mentioned medications should be possible by detection of cathinone 
or methcathinone. For the above-mentioned reasons, an analytical procedure to be 
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used in this context should allow selective detection of all analytes including 
differentiation of the diastereomers as well as their reliable quantification.  
So far, procedures for separation, detection and quantification of all the 
above-mentioned phenalkylamines in blood plasma have not been published in contrast 
to methods for quantification of single substances of this group or combinations of a few 
of them. For analysis of ephedrine and related compounds in biological fluids, various 
procedures were published using HPLC,26,88-90 liquid chromatography coupled with a 
single-stage mass spectrometer (LC-MS)91,92 or tandem mass spectrometer (LC-
MS/MS),31,93-95 or GC-MS.28,94 For the detection and quantification of mescaline, several 
procedures were published96-98 as well as for monitoring khat abuse.33,35,99  
The aim of the presented study was to develop a multi-analyte procedure for separation, 
detection and quantification of all the above-mentioned phenalkylamines in blood 
plasma using LC-MS/MS in the electrospray ionization (ESI) mode. The quantification 
procedure had to be validated and tested for applicability in clinical and forensic 
toxicology.  
 
1.2.4 Toxic Alkaloids 
Based on the statistics of the 2005 annual report of poison information center of 
northern Germany,1 besides cardiac glycosides, the following alkaloids were most 
frequently involved in plant poisonings: aconitine, atropine, colchicine, coniine, cytisine, 
nicotine, physostigmine, scopolamine.  
For diagnosis and prognosis of such poisonings, analytical methods for detection and 
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plasma analysis of coniine and cytisine are not available in the literature at all. 
Therefore, the first aim of the presented study was to develop a multi-analyte procedure 
for detection and validated quantification of aconitine, atropine, colchicine, coniine, 
cytisine, nicotine and its metabolite cotinine, physostigmine, and scopolamine in blood 
plasma. Development of an LC-MS-based assay seemed most promising due to soft 
ionization, and high selectivity and sensitivity. Tandem MS apparatus are more sensitive 
and selective, but much more expensive than single stage MS. This raised the question 
whether tandem MS is actually necessary for detection and quantification of these 
alkaloids. Therefore, the second aim of the study was to compare a single stage vs. a 
tandem MS instrument with respect to selectivity, sensitivity, accuracy and precision 
after identical sample preparation.  
 
1.3 SUMMARY OF THE AIMS OF THE PRESENTED STUDIES 
In summary, it can be stated that for some of the presented single substances and 
substance classes a variety of analytical procedures has been developed over the 
years, but universal procedures covering more than a few toxic herbal drugs remain to 
be elaborated due to the different physiochemical properties of the active ingredients of 
herbal drugs. One systematic toxicological procedure will not cover all compounds of 
interest. Therefore, development or adaption of different procedures is necessary.  
The aim of the presented thesis was to develop methods for detection and validated 
quantification. The following drugs or drug clases were included in this method 
development: 
• Laxatives 
• Ingredients of Nutmeg 
• Herbal Phenalkylamines 
• Toxic alkaloids 
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2 EXPERIMENTAL PROCEDURES 
2.1 CHEMICALS AND REAGENTS 
2.1.1 Laxatives 
Bisacodyl diphenol was obtained from Sigma, Taufkirchen (Germany). Rhein, 
phenolphthalein, diethyl ether, ethyl acetate, methanol and methyl iodide were obtained 
from Merck, Darmstadt (Germany). Tetrahexylammonium hydrogen sulfate and toluene 
were obtained from Fluka, Neu-Ulm (Germany). All chemicals except methyl iodide (for 
synthesis) were of analytical grade. The solid-phase extraction (SPE) columns (Isolute 
Diol, 500 mg, 10 ml XL) were obtained from Separtis, Grenzach-Wylen (Germany). 
For the synthesis of dimethylated bisacodyl diphenol (bisacodyl diphenol-2ME) and 
dimethylated phenolphthalein (phenolphthalein-2ME), 1 ml of a methanolic 1 mg/ml 
solution of each analyte was transferred to a 10 ml glass tube, each. After addition of 
2 ml of freshly prepared diazomethane solution in diethyl ether, the glass tube was 
closed and the solution was incubated for 48 hours at room temperature in the dark. 
Diazomethane was synthesized according to the procedure of McKay et al. using 
1-methyl-3-nitro-1-nitroso-3-nitroguanidine, KOH and diethyl ether.130 After incubation, 
the solution was evaporated to dryness under a stream of nitrogen at room temperature. 
The residue was dissolved in 1 ml of methanol. The purity of the methyl derivatives was 
checked by GC-MS. 
Trimethylated rhein (rhein-3ME) was synthesized by extractive methylation. Two ml of 
an aqueous solution containing 50 mg/ml of rhein were extracted as described below 
(see 2.3.1). After evaporation, the residue was redissolved in water and extractive 
methylation was repeated. After the second evaporation, the residue was weighed and 
dissolved in methanol. The purity of the derivative was checked by GC-MS. 
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2.1.2 Ingredients of Nutmeg 
Elemicin was provided by cc chemical consulting (Berlin, Germany) for research 
purposes. Myristicin and safrole were obtained from Sigma (Taufkirchen, Germany) and 
all other chemicals and biochemicals (analytical grade) were obtained from Merck 
(Darmstadt, Germany).  
 
2.1.3 Herbal Phenalkylamines 
Ammonium formate (analytical grade), free bases of ephedrine, methylephedrine, 
methylpseudoephedrine, norephedrine, norpseudoephedrine, pseudoephedrine, and 
synephrine were obtained from Fluka (Neu-Ulm, Germany). Methanolic solutions of 
cathinone, methcathinone, mescaline and of the internal standards (IS) ephedrine-d3, 
norephdrine-d3 and mescaline-d9 were obtained from Promochem (Wesel, Germany). 
Acetonitrile and water (both HPLC grade) and all other chemicals (analytical grade) 
were obtained from E. Merck (Darmstadt, Germany). Varian Bond Elute Certify 
cartridges (130 mg; 3 ml) were obtained from Varian (Darmstadt, Germany). 
 
2.1.4 Toxic Alkaloids 
Aconitine, atropine, colchicine, and scopolamine were obtained from Fluka (Neu-Ulm, 
Germany), cytisine from ChromaDex (St. Ana, USA), and physostigmine from Koehler 
Chemie (Alsbach-Haehnlein, Germany). Coniine was a kind gift of the Institute of 
Pharmaceutical Biology (Saarbruecken, Germany). Methanolic solutions of cotinine and 
nicotine, as well as the IS cotinine-d3, benzoylecgonine-d3, and trimipramine-d3 were 
obtained from Promochem (Wesel, Germany). Acetonitrile and water (both HPLC 
grade) and all other chemicals (analytical grade) were obtained from E. Merck 
(Darmstadt, Germany). Varian Bond Elute Certify cartridges (130 mg; 3 ml) were 
obtained from Varian (Darmstadt, Germany). 
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Pharmaceutical Biology (Saarbruecken, Germany). Methanolic solutions of cotinine and 
nicotine, as well as the IS cotinine-d3, benzoylecgonine-d3, and trimipramine-d3 were 
obtained from Promochem (Wesel, Germany). Acetonitrile and water (both HPLC 
grade) and all other chemicals (analytical grade) were obtained from E. Merck 
(Darmstadt, Germany). Varian Bond Elute Certify cartridges (130 mg; 3 ml) were 
obtained from Varian (Darmstadt, Germany). 
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2.2 BIOSAMPLES 
2.2.1 Urine Samples for the Study on Analysis of Laxatives 
Blank urine samples used for method development as well as for stability, recovery, and 
limit of detection (LOD) experiments were obtained from healthy drug-free volunteers. 
Duration of detectability experiments were carried out using urine samples from healthy 
volunteers who received one lowest therapeutic dose of senna extract containing 7 mg 
sennoside B or of one lowest therapeutic dose of sodium picosulfate (5 mg) after 
informed consent according the declaration of Helsinki. Urine samples from authentic 
cases had been submitted to our laboratory for toxicological analysis.  
 
2.2.2 Urine Samples for the Study on Analysis of Ingredients of Nutmeg 
The investigations were performed using urine of male rats (Wistar, Ch. River, 
Sulzfleck, Germany) for toxicological diagnostic reasons according to the corresponding 
German Animal Protecting law. The rats were administered a single 100 mg/kg body 
mass (BM) dose of elemicin, myristicin, and safrole for metabolism studies or a single 
500 mg/kg BM dose of grounded nutmeg from two different batches for the STA study in 
aqueous suspension (final volume 1 ml each) by gastric intubation (n = 2 for each 
substance and dose). Urine was collected separately from the faeces over a 24 h 
period. All samples were directly analyzed. Blank rat urine samples were collected 
before drug administration to check whether they were free of interfering compounds.  
Human urine samples were submitted to our laboratory for toxicological analysis. They 
were collected from an inpatient of a psychiatric hospital who stated after being 
informed on the result of the urine screening that he had taken powder of about five 
nutmegs. The only registered symptom was vomiting.  
 
2.2.3 Plasma Samples for the Study on Analysis of Herbal Phenalkylamines 
Pooled human blank plasma samples were used for development and validation of the 
procedure and were obtained from a local blood bank. Blood samples for selectivity 
experiments were from therapeutic drug monitoring (TDM) cases or intoxication cases 
and had been submitted to our laboratory by various hospitals.  
18 2 Experimental procedures 
 
 
2.2 BIOSAMPLES 
2.2.1 Urine Samples for the Study on Analysis of Laxatives 
Blank urine samples used for method development as well as for stability, recovery, and 
limit of detection (LOD) experiments were obtained from healthy drug-free volunteers. 
Duration of detectability experiments were carried out using urine samples from healthy 
volunteers who received one lowest therapeutic dose of senna extract containing 7 mg 
sennoside B or of one lowest therapeutic dose of sodium picosulfate (5 mg) after 
informed consent according the declaration of Helsinki. Urine samples from authentic 
cases had been submitted to our laboratory for toxicological analysis.  
 
2.2.2 Urine Samples for the Study on Analysis of Ingredients of Nutmeg 
The investigations were performed using urine of male rats (Wistar, Ch. River, 
Sulzfleck, Germany) for toxicological diagnostic reasons according to the corresponding 
German Animal Protecting law. The rats were administered a single 100 mg/kg body 
mass (BM) dose of elemicin, myristicin, and safrole for metabolism studies or a single 
500 mg/kg BM dose of grounded nutmeg from two different batches for the STA study in 
aqueous suspension (final volume 1 ml each) by gastric intubation (n = 2 for each 
substance and dose). Urine was collected separately from the faeces over a 24 h 
period. All samples were directly analyzed. Blank rat urine samples were collected 
before drug administration to check whether they were free of interfering compounds.  
Human urine samples were submitted to our laboratory for toxicological analysis. They 
were collected from an inpatient of a psychiatric hospital who stated after being 
informed on the result of the urine screening that he had taken powder of about five 
nutmegs. The only registered symptom was vomiting.  
 
2.2.3 Plasma Samples for the Study on Analysis of Herbal Phenalkylamines 
Pooled human blank plasma samples were used for development and validation of the 
procedure and were obtained from a local blood bank. Blood samples for selectivity 
experiments were from therapeutic drug monitoring (TDM) cases or intoxication cases 
and had been submitted to our laboratory by various hospitals.  
18 2 Experimental procedures 
 
 
2.2 BIOSAMPLES 
2.2.1 Urine Samples for the Study on Analysis of Laxatives 
Blank urine samples used for method development as well as for stability, recovery, and 
limit of detection (LOD) experiments were obtained from healthy drug-free volunteers. 
Duration of detectability experiments were carried out using urine samples from healthy 
volunteers who received one lowest therapeutic dose of senna extract containing 7 mg 
sennoside B or of one lowest therapeutic dose of sodium picosulfate (5 mg) after 
informed consent according the declaration of Helsinki. Urine samples from authentic 
cases had been submitted to our laboratory for toxicological analysis.  
 
2.2.2 Urine Samples for the Study on Analysis of Ingredients of Nutmeg 
The investigations were performed using urine of male rats (Wistar, Ch. River, 
Sulzfleck, Germany) for toxicological diagnostic reasons according to the corresponding 
German Animal Protecting law. The rats were administered a single 100 mg/kg body 
mass (BM) dose of elemicin, myristicin, and safrole for metabolism studies or a single 
500 mg/kg BM dose of grounded nutmeg from two different batches for the STA study in 
aqueous suspension (final volume 1 ml each) by gastric intubation (n = 2 for each 
substance and dose). Urine was collected separately from the faeces over a 24 h 
period. All samples were directly analyzed. Blank rat urine samples were collected 
before drug administration to check whether they were free of interfering compounds.  
Human urine samples were submitted to our laboratory for toxicological analysis. They 
were collected from an inpatient of a psychiatric hospital who stated after being 
informed on the result of the urine screening that he had taken powder of about five 
nutmegs. The only registered symptom was vomiting.  
 
2.2.3 Plasma Samples for the Study on Analysis of Herbal Phenalkylamines 
Pooled human blank plasma samples were used for development and validation of the 
procedure and were obtained from a local blood bank. Blood samples for selectivity 
experiments were from therapeutic drug monitoring (TDM) cases or intoxication cases 
and had been submitted to our laboratory by various hospitals.  
18 2 Experimental procedures 
 
 
2.2 BIOSAMPLES 
2.2.1 Urine Samples for the Study on Analysis of Laxatives 
Blank urine samples used for method development as well as for stability, recovery, and 
limit of detection (LOD) experiments were obtained from healthy drug-free volunteers. 
Duration of detectability experiments were carried out using urine samples from healthy 
volunteers who received one lowest therapeutic dose of senna extract containing 7 mg 
sennoside B or of one lowest therapeutic dose of sodium picosulfate (5 mg) after 
informed consent according the declaration of Helsinki. Urine samples from authentic 
cases had been submitted to our laboratory for toxicological analysis.  
 
2.2.2 Urine Samples for the Study on Analysis of Ingredients of Nutmeg 
The investigations were performed using urine of male rats (Wistar, Ch. River, 
Sulzfleck, Germany) for toxicological diagnostic reasons according to the corresponding 
German Animal Protecting law. The rats were administered a single 100 mg/kg body 
mass (BM) dose of elemicin, myristicin, and safrole for metabolism studies or a single 
500 mg/kg BM dose of grounded nutmeg from two different batches for the STA study in 
aqueous suspension (final volume 1 ml each) by gastric intubation (n = 2 for each 
substance and dose). Urine was collected separately from the faeces over a 24 h 
period. All samples were directly analyzed. Blank rat urine samples were collected 
before drug administration to check whether they were free of interfering compounds.  
Human urine samples were submitted to our laboratory for toxicological analysis. They 
were collected from an inpatient of a psychiatric hospital who stated after being 
informed on the result of the urine screening that he had taken powder of about five 
nutmegs. The only registered symptom was vomiting.  
 
2.2.3 Plasma Samples for the Study on Analysis of Herbal Phenalkylamines 
Pooled human blank plasma samples were used for development and validation of the 
procedure and were obtained from a local blood bank. Blood samples for selectivity 
experiments were from therapeutic drug monitoring (TDM) cases or intoxication cases 
and had been submitted to our laboratory by various hospitals.  
2.2 Biosamples 19 
 
 
Applicability experiments were carried out using plasma samples from healthy 
volunteers taken one hour after application of 30 mg of pseudoephedrine (contained in 
Aspirin complex®), 6.2 mg of ephedrine (contained in Wick MediNait®), or 10 g of an 
aqueous extract of Herba Ephedra after informed consent according to the declaration 
of Helsinki. Herba Ephedra was obtained from a local pharmacy and decocted for 5 min 
with boiled water. The dose was selected according to recommendations of using Herba 
Ephedra as stimulant.25 
 
2.2.4 Plasma Samples for the Study on Analysis of Toxic Alkaloids 
Human blank plasma samples and blood samples from drug free volunteers were used 
for development of selectivity experiments and validation of the procedure. They were 
obtained from a local blood bank. Applicability experiments were carried out using 
plasma samples from poisoning cases sent to our laboratory for toxicological analysis.  
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2.3 SAMPLE PREPARATIONS 
2.3.1 Sample Preparation for Analysis of Laxatives 
A 2-ml portion of urine was adjusted to pH 5.2 with acetic acid (1 mol/L) and incubated 
in a water bath at 52°C for 90 min with 100 µl of a mixture (100 000 Fishman units 
per ml) of glucuronidase (EC no. 3.2.1.31) and arylsulfatase (EC no. 3.1.6.1) from Helix 
pomatia then mixed in a centrifugation tube with 2 ml of the phase-transfer reagent 
consisting of 0.02 M tetrahexylammonium (THA) hydrogensulfate in 1 M sodium 
phosphate solution (pH 12). After addition of 6 ml of 1 M methyl iodide in toluene, the 
closed tube was shaken in a heating block at 50°C for 30 min. After phase separation 
by centrifugation at 1500 × g for 3 min, the organic phase containing the analytes and 
THA salts was transferred to the SPE column conditioned as follows: 5 ml of methanol 
at a flow rate of 10 ml/min, drying the column under vacuum for 15 seconds, 5 ml of 
toluene at a flow rate of 10 ml/min. The organic phase was rinsed through the sorbent 
bed at a flow rate of 3 ml/min to remove the THA salts from the organic phase and the 
eluate was collected. The part of the analytes also adsorbed on the sorbent was 
selectively eluted with 5 ml of diethyl ether/ethyl acetate (95: 5, v/v) at a flow rate of 
3 ml/min and the eluate was collected. The combined eluates were carefully evaporated 
to dryness at 60°C (reduced pressure, 30-50 kPa). The residue was dissolved in 50 µl 
of ethyl acetate and a 1 µl-aliquot of this extract was injected into the GC-MS system. 
 
2.3.2 Sample Preparation for Analysis of Ingredients of Nutmeg  
2.3.2.1 Sample Preparation for Identification of Metabolites by GC-MS 
A 5-ml portion of rat or human urine was adjusted to pH 5.2 with acetic acid (1 mol/l) 
and incubated at 37°C for 12 h with 100 µl of a mixture (100 000 Fishman units per ml) 
of glucuronidase (EC no. 3.2.1.31) and arylsulfatase (EC no. 3.1.6.1) from Helix 
pomatia, then adjusted to pH 8-9 and extracted with 5 ml of a dichloromethane-
isopropanol-ethyl acetate mixture (1:1:3; v/v/v). After phase separation by 
centrifugation, the organic layer was transferred into glass flasks and carefully 
evaporated to dryness at 75°C under vacuum. The residue was derivatized by 
acetylation or left underivatized and dissolved in 100 µl of methanol. Acetylation was 
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conducted with 100 µl of an acetic anhydride-pyridine mixture (3:2; v/v) for 5 min under 
microwave irradiation at about 440 W. After careful evaporation, the residue was 
dissolved in 100 µl of methanol and 2 µl of this solution were injected into the GC-MS. 
The same procedure with the exception of enzymatic hydrolysis was used to study 
whether metabolites of nutmeg ingredients were excreted as glucuronide and/or sulfate 
conjugates. 
A second urine sample was worked up as described above, but pH was adjusted to 4-5 
and the corresponding extract was methylated and subsequently acetylated. After 
reconstitution of the extraction residue in 100 µl of methanol, methylation was 
conducted with 200 µl of a solution of diazomethane in diethyl ether, synthesized 
according to the procedure of McKay et al.130 The reaction vials were sealed and left at 
room temperature for 15 min. Thereafter, the mixture was once again carefully 
evaporated to dryness under a stream of nitrogen, the residue acetylated as described 
above, and finally the evaporated residue redissolved in 100 µl of methanol and 2 µl of 
this sample was injected into the GC-MS.84  
 
2.3.2.2 Sample Preparation for Systematic Toxicological Analysis by GC-MS 
The urine samples (5 ml) were divided into two aliquots. One aliquot was refluxed with 
1 ml of 37% hydrochloric acid for 15 min. Following hydrolysis, the sample was mixed 
with 2 ml of 2.3 mol/l aqueous ammonium sulfate and 1.5 ml of 10 mol/l aqueous 
sodium hydroxide to obtain a pH value of 8-9. Before extraction, the other aliquot of 
unhydrolyzed urine was added and this solution was extracted with 5 ml of a 
dichloromethane-isopropanol-ethyl acetate mixture (1:1:3; v/v/v). After phase separation 
by centrifugation, the organic layer was transferred into glass flasks and carefully 
evaporated to dryness at 75°C under vacuum. The residue was derivatized by 
acetylation with 100 µl of an acetic anhydride-pyridine mixture (3:2; v/v) for 5 min under 
microwave irradiation at about 440 W. After careful evaporation of the derivatization 
mixture, the residue was dissolved in 100 µl of methanol and 2 µl of this sample were 
injected into the GC-MS. 
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2.4 APPARATUS AND CONDITIONS 
2.4.1 Screening and Identification of Laxatives 
2.4.1.1 Apparatus 
The samples were incubated in a heating block fixed to a multifix shaker S 300 
(Schwinherr, Schwäbisch Gmünd, Germany). A Vac-Master V-10 (ICT, Bad Homburg, 
Germany) was used for manual SPE. The samples were analyzed using a Hewlett 
Packard (Agilent, Waldbronn, Germany) HP 6890 Series GC system combined with an 
HP 5972 Series mass selective detector, an HP 6890 Series injector and an HP Chem 
Station G1701AA version A.03.00. 
 
2.4.1.2 GC Conditions 
The GC conditions were as follows: split-less injection mode; column, HP-1 capillary (12 
m x 0.2 mm I.D.), cross-linked methyl silicone, 330 nm film thickness; injection port 
temperature, 280°C; carrier gas, helium; flow-rate 1 ml/min; column temperature, 
programmed from 100-310°C at 30°/min, initial time 3 min, final time 8 min. 
 
2.4.1.3 MS Conditions for Screening Procedure 
The MS conditions for the screening procedure were as follows: full scan mode, mass to 
charge ratio (m/z) 50-550 u; EI mode: ionization energy, 70 eV; ion source temperature, 
280°C. 
 
2.4.1.4 MS Conditions for Recovery Experiments 
Mass fragmentography in selected-ion monitoring (SIM) mode was used with the 
following program: solvent delay, 3 min; time window A, 3.00-9.00 min, m/z 305 (target 
ion, t), 290 for bisacodyl diphenol-2ME; time window B, 9.01-18.00 min m/z 311 (t), 326 
for rhein-3ME and m/z 271 (t), 346 for phenolphthalein-2ME. 
 
 
2.4 Apparatus and Conditions 23 
 
 
2.4 APPARATUS AND CONDITIONS 
2.4.1 Screening and Identification of Laxatives 
2.4.1.1 Apparatus 
The samples were incubated in a heating block fixed to a multifix shaker S 300 
(Schwinherr, Schwäbisch Gmünd, Germany). A Vac-Master V-10 (ICT, Bad Homburg, 
Germany) was used for manual SPE. The samples were analyzed using a Hewlett 
Packard (Agilent, Waldbronn, Germany) HP 6890 Series GC system combined with an 
HP 5972 Series mass selective detector, an HP 6890 Series injector and an HP Chem 
Station G1701AA version A.03.00. 
 
2.4.1.2 GC Conditions 
The GC conditions were as follows: split-less injection mode; column, HP-1 capillary (12 
m x 0.2 mm I.D.), cross-linked methyl silicone, 330 nm film thickness; injection port 
temperature, 280°C; carrier gas, helium; flow-rate 1 ml/min; column temperature, 
programmed from 100-310°C at 30°/min, initial time 3 min, final time 8 min. 
 
2.4.1.3 MS Conditions for Screening Procedure 
The MS conditions for the screening procedure were as follows: full scan mode, mass to 
charge ratio (m/z) 50-550 u; EI mode: ionization energy, 70 eV; ion source temperature, 
280°C. 
 
2.4.1.4 MS Conditions for Recovery Experiments 
Mass fragmentography in selected-ion monitoring (SIM) mode was used with the 
following program: solvent delay, 3 min; time window A, 3.00-9.00 min, m/z 305 (target 
ion, t), 290 for bisacodyl diphenol-2ME; time window B, 9.01-18.00 min m/z 311 (t), 326 
for rhein-3ME and m/z 271 (t), 346 for phenolphthalein-2ME. 
 
 
2.4 Apparatus and Conditions 23 
 
 
2.4 APPARATUS AND CONDITIONS 
2.4.1 Screening and Identification of Laxatives 
2.4.1.1 Apparatus 
The samples were incubated in a heating block fixed to a multifix shaker S 300 
(Schwinherr, Schwäbisch Gmünd, Germany). A Vac-Master V-10 (ICT, Bad Homburg, 
Germany) was used for manual SPE. The samples were analyzed using a Hewlett 
Packard (Agilent, Waldbronn, Germany) HP 6890 Series GC system combined with an 
HP 5972 Series mass selective detector, an HP 6890 Series injector and an HP Chem 
Station G1701AA version A.03.00. 
 
2.4.1.2 GC Conditions 
The GC conditions were as follows: split-less injection mode; column, HP-1 capillary (12 
m x 0.2 mm I.D.), cross-linked methyl silicone, 330 nm film thickness; injection port 
temperature, 280°C; carrier gas, helium; flow-rate 1 ml/min; column temperature, 
programmed from 100-310°C at 30°/min, initial time 3 min, final time 8 min. 
 
2.4.1.3 MS Conditions for Screening Procedure 
The MS conditions for the screening procedure were as follows: full scan mode, mass to 
charge ratio (m/z) 50-550 u; EI mode: ionization energy, 70 eV; ion source temperature, 
280°C. 
 
2.4.1.4 MS Conditions for Recovery Experiments 
Mass fragmentography in selected-ion monitoring (SIM) mode was used with the 
following program: solvent delay, 3 min; time window A, 3.00-9.00 min, m/z 305 (target 
ion, t), 290 for bisacodyl diphenol-2ME; time window B, 9.01-18.00 min m/z 311 (t), 326 
for rhein-3ME and m/z 271 (t), 346 for phenolphthalein-2ME. 
 
 
2.4 Apparatus and Conditions 23 
 
 
2.4 APPARATUS AND CONDITIONS 
2.4.1 Screening and Identification of Laxatives 
2.4.1.1 Apparatus 
The samples were incubated in a heating block fixed to a multifix shaker S 300 
(Schwinherr, Schwäbisch Gmünd, Germany). A Vac-Master V-10 (ICT, Bad Homburg, 
Germany) was used for manual SPE. The samples were analyzed using a Hewlett 
Packard (Agilent, Waldbronn, Germany) HP 6890 Series GC system combined with an 
HP 5972 Series mass selective detector, an HP 6890 Series injector and an HP Chem 
Station G1701AA version A.03.00. 
 
2.4.1.2 GC Conditions 
The GC conditions were as follows: split-less injection mode; column, HP-1 capillary (12 
m x 0.2 mm I.D.), cross-linked methyl silicone, 330 nm film thickness; injection port 
temperature, 280°C; carrier gas, helium; flow-rate 1 ml/min; column temperature, 
programmed from 100-310°C at 30°/min, initial time 3 min, final time 8 min. 
 
2.4.1.3 MS Conditions for Screening Procedure 
The MS conditions for the screening procedure were as follows: full scan mode, mass to 
charge ratio (m/z) 50-550 u; EI mode: ionization energy, 70 eV; ion source temperature, 
280°C. 
 
2.4.1.4 MS Conditions for Recovery Experiments 
Mass fragmentography in selected-ion monitoring (SIM) mode was used with the 
following program: solvent delay, 3 min; time window A, 3.00-9.00 min, m/z 305 (target 
ion, t), 290 for bisacodyl diphenol-2ME; time window B, 9.01-18.00 min m/z 311 (t), 326 
for rhein-3ME and m/z 271 (t), 346 for phenolphthalein-2ME. 
 
 
24 2 Experimental procedures 
 
 
2.4.1.5 GC-MS Screening Procedure 
The laxatives and/or their metabolites were screened for by mass chromatography 
extracting characteristic fragment ions from the total ion current. The following ions were 
used for this purpose: m/z 305, 290, 335, 320, 365, 350, 311, 326, 271 and 346. For 
matters of convenience, this operation was carried out by a user-defined macro. 
Positive peaks were identified by visual or computerized comparison of the peaks 
underlying mass spectra with reference spectra.  
 
 
2.4.2 Screening and Identification of Ingredients of Nutmeg 
2.4.2.1 Apparatus 
The extracts were analyzed using a Hewlett Packard (Agilent, Waldbronn, Germany) 
5890 Series II gas chromatograph combined with a HP 5972A MSD mass spectrometer 
and a HP MS ChemStation (DOS series) with HP G1034C software version C03.00. 
Analyte separation was achieved on a fused silica capillary column (HP-1MS, 12 m x 
0.2 mm i.d., film thickness 0.33 µm). The GC conditions were as follows: split-less 
injection mode; column, injection port temperature, 280°C; carrier gas, helium; flow-rate 
1 ml/min; column temperature, programmed from 100-310°C at 30°/min, initial time 
3 min, final time 8 min. The MS conditions were as follows: full-scan mode, m/z 50-
550 u; EI mode, ionization energy, 70 eV; ion source temperature, 220°C; capillary 
direct interface, heated at 280°C.  
 
2.4.2.2 GC-MS Procedure for Identification of Metabolites 
The urinary metabolites of elemicin, myristicin, and safrole were separated by GC and 
identified by EI MS after enzymatic hydrolysis, extraction, acetylation, 
trifluoroacetylation, methylation plus acetylation or without derivatization. The postulated 
structures of the metabolites were deduced from the fragments detected in the EI mode 
which were interpreted in correlation to those of the parent compound according to the 
rules described by e.g. McLafferty and Turecek 131 and Smith and Busch 132. 
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2.4.2.3 GC-MS Procedure for Systematic Toxicological Analysis 
The extracted and derivatized metabolites of elemicin, myristicin, and safrole were 
separated by GC. They were screened for and identified as follows: mass 
chromatography with the selected ions m/z 150, 164, 165, 180, 194, 252, and 266 was 
used for screening. These ions were selected from the mass spectra recorded during 
this study. Generation of the mass chromatograms could be started by clicking the 
corresponding pull down menu which executes the user defined macros.79,133 The 
identity of the peaks in the mass chromatograms was confirmed by computerized 
comparison134 of the mass spectra underlying the peaks (after background subtraction) 
with reference spectra recorded during this study.  
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2.4.3 Screening and Identification of Herbal Phenalkylamines 
2.4.3.1 Apparatus 
The studied analytes were separated using a Shimadzu integrated HPLC system which 
consisted of a Shimadzu CBM 20 A controller, two Shimadzu LC 20 AD pumps 
including a degasser, a Shimadzu SIL 20 AC autosampler, and a Shimadzu CTO 20 AC 
column oven. The analytes were detected using an Applied Biosystems 3200 Q TRAP 
Linear Ion Trap Quadrupole Mass Spectrometer with Analyst Software (Version 1.4.1) 
equipped with a Turbo V™ Ion Source operated in the ESI mode. 
 
2.4.3.2  LC Conditions 
Gradient elution was performed on an Agilent Zorbax® strong cation exchange (SCX) 
column (5 µm, 150 x 2.1 mm) as stationary phase and a Wicom SCX guard column 
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settings are summarized in Table 2.1. The method was checked for cross-talk by 
injection of the single analytes. Q1 and Q3 were operated in Unit resolution. 
 
Table 2.1. Analytes, MRM transitions and parameter settings including declustering potential (DP), 
entrance potential (ENP), collision cell entrance potential (CEP), and collision energy (CE). Target 
transitions are marked with (t), qualifier transitions marked with (q). 
 
Analyte Q 1 Mass, u Q 3 Mass, u DP, V ENP, V CEP, V CE, eV
107.10 (t) 36.00 10.00 14.43 35.00
91.20 (q) 36.00 10.00 14.43 25.00
Cathinone 150.06
77.00 (q) 36.00 10.00 14.43 49.00
117.10 (t) 10.00 5.00 14.88 27.00
91.00 (q) 10.00 5.00 14.88 43.00
Ephedrine 166.07
133.10 (q) 10.00 5.00 14.88 27.00
130.90 (t) 10.00 4.00 14.82 27.00
130.10 (q) 10.00 4.00 14.82 43.00
Methcathinone 164.08
77.00 (q) 10.00 4.00 14.82 59.00
117.10 (t) 10.00 4.50 15.27 27.00
147.10 (q) 10.00 4.50 15.27 27.00
Methylephedrine 180.12
91.10 (q) 10.00 4.50 15.27 41.00
195.10 (t) 10.00 6.00 16.17 23.00
180.20 (q) 10.00 6.00 16.17 23.00
Mescaline 212.09
77.10 (q) 10.00 6.00 16.17 59.00
147.20 (t) 10.00 3.00 15.27 27.00
91.10 (q) 10.00 3.00 15.27 47.00
Methylpseudoephedrine 180.10
146.00 (q) 10.00 3.00 15.27 33.00
117.00 (t) 10.00 4.00 14.49 23.00
115.00 (q) 10.00 4.00 14.49 29.00
Norephedrine 152.08
91.00 (q) 10.00 4.00 14.49 39.00
117.10 (t) 10.00 4.50 14.49 23.00
115.00 (q) 10.00 4.50 14.49 23.00
Norpseudoephedrine 
 
Norpseudoephedrine 
152.08
152.08 91.00 (q) 10.00 4.50 14.49 37.00
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91.00 (t) 10.00 4.00 14.88 45.00
133.00 (q) 10.00 4.00 14.88 27.00
Pseudoephedrine 166.10
115.00 (q) 10.00 4.00 14.88 35.00
117.00 (t) 10.00 3.00 14.43 29.00
105.10 (q) 10.00 3.00 14.43 25.00
Synephrine 150.08
77.10 (q) 10.00 3.00 14.43 47.00
117.10 (t) 21.00 10.50 14.96 27.00
115.10 (q) 21.00 10.50 14.96 37.00
Ephedrine-d3 169.18
91.10 (q) 21.00 10.50 14.96 45.00
204.20 (t) 21.00 9.00 16.42 15.00
186.20 (q) 21.00 9.00 16.42 25.00
Mescaline-d9 221.26
170.20 (q) 21.00 9.00 16.42 31.00
119.10 (t) 16.00 9.00 14.57 25.00
120.10 (q) 16.00 9.00 14.57 25.00
Norephedrine-d3 155.19
117.10 (q) 16.00 9.00 14.57 33.00
 
2.4.4 Screening and Identification of Toxic Alkaloids 
2.4.4.1 Apparatus 
The LC-MS system was as follows: Agilent Technologies (AT, Waldbronn, Germany) 
AT 1100 Series HPLC system which consisted of a degasser, a binary pump and an 
autosampler. As detector an AT 1100 MSD Mass Spectrometer equipped with an 
atmospheric pressure chemical ionization (APCI) source was used. In the following, for 
this system the term single stage MS is used.  
The LC-MS/MS system was as follows: Shimadzu integrated HPLC system which 
consisted of a Shimadzu CBM 20 A controller, two Shimadzu LC 20 AD pumps 
including a degasser, a Shimadzu SIL 20 AC autosampler, and a Shimadzu CTO 20 AC 
column oven. As detector an Applied Biosystems 3200 Q TRAP Linear Ion Trap 
Quadrupole Mass Spectrometer with Analyst Software (Version 1.4.1) equipped with a 
Turbo V™ Ion Source operated in the ESI mode was used. In the following, for this 
system the term tandem MS is used. 
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2.4.4.2 LC Conditions  
The following LC conditions were identical in both systems. Gradient elution was 
performed on a Merck LiChroCART column (125 x 2 mm internal diameter) with 
Superspher60 RP Select B as stationary phase and a LiChroCART 10-2 Superspher 
60 RP Select B guard column. The mobile phase consisted of 50 mM aqueous 
ammonium formate adjusted to pH 3.5 with formic acid (eluent A) and acetonitrile 
(eluent B). Before use, the mobile phases were degassed for 30 min in an ultrasonic 
bath. During use, the mobile phase was degassed by the corresponding integrated 
degasser. Before starting analysis, the HPLC systems were equilibrated for 10 min with 
a mixture of 90 % of eluent A and 10 % of eluent B. The gradient and the flow rate were 
programmed as follows: 0.00-2.00 min 10% B (flow: 0.4 ml/min), 2.01-5.00 min gradient 
increase to 80% B (flow: 0.6 ml/min), 5.01-7.00 min 80% B (flow: 0.60 ml/min) 7.01-
10.00 min 10% B (flow: 0.4 ml/min) for re-equilibration of the HPLC column. The column 
oven was set at 25°C.  
 
2.4.4.3 Single stage and Tandem MS Conditions  
For single stage MS, the following APCI inlet conditions were selected: drying gas, 
nitrogen (12 l/min, 350°C) and nebulizer gas, nitrogen (25 psi; 172.5 kPa); capillary 
voltage, 4000 V; vaporizer temperature, 400°C; corona current, 5.0 µA. The MS was 
operated in positive scan mode with a scan range from m/z 50 to 800 on MSD 1 for 
screening and identification, and in SIM mode on MSD 2 for quantification. For 
quantification, the SIM mode at 100 and 200 V fragmentor voltage with different gain 
values was used. The settings are given in Table 2.2. Tuning of the MS was performed 
with the help of the autotune feature of the LC-MS ChemStation software (rev. A.08.03) 
using the APCI acetonitrile solution tuning mix supplied by the manufacturer. 
2.4 Apparatus and Conditions 29 
 
 
 
2.4.4.2 LC Conditions  
The following LC conditions were identical in both systems. Gradient elution was 
performed on a Merck LiChroCART column (125 x 2 mm internal diameter) with 
Superspher60 RP Select B as stationary phase and a LiChroCART 10-2 Superspher 
60 RP Select B guard column. The mobile phase consisted of 50 mM aqueous 
ammonium formate adjusted to pH 3.5 with formic acid (eluent A) and acetonitrile 
(eluent B). Before use, the mobile phases were degassed for 30 min in an ultrasonic 
bath. During use, the mobile phase was degassed by the corresponding integrated 
degasser. Before starting analysis, the HPLC systems were equilibrated for 10 min with 
a mixture of 90 % of eluent A and 10 % of eluent B. The gradient and the flow rate were 
programmed as follows: 0.00-2.00 min 10% B (flow: 0.4 ml/min), 2.01-5.00 min gradient 
increase to 80% B (flow: 0.6 ml/min), 5.01-7.00 min 80% B (flow: 0.60 ml/min) 7.01-
10.00 min 10% B (flow: 0.4 ml/min) for re-equilibration of the HPLC column. The column 
oven was set at 25°C.  
 
2.4.4.3 Single stage and Tandem MS Conditions  
For single stage MS, the following APCI inlet conditions were selected: drying gas, 
nitrogen (12 l/min, 350°C) and nebulizer gas, nitrogen (25 psi; 172.5 kPa); capillary 
voltage, 4000 V; vaporizer temperature, 400°C; corona current, 5.0 µA. The MS was 
operated in positive scan mode with a scan range from m/z 50 to 800 on MSD 1 for 
screening and identification, and in SIM mode on MSD 2 for quantification. For 
quantification, the SIM mode at 100 and 200 V fragmentor voltage with different gain 
values was used. The settings are given in Table 2.2. Tuning of the MS was performed 
with the help of the autotune feature of the LC-MS ChemStation software (rev. A.08.03) 
using the APCI acetonitrile solution tuning mix supplied by the manufacturer. 
2.4 Apparatus and Conditions 29 
 
 
 
2.4.4.2 LC Conditions  
The following LC conditions were identical in both systems. Gradient elution was 
performed on a Merck LiChroCART column (125 x 2 mm internal diameter) with 
Superspher60 RP Select B as stationary phase and a LiChroCART 10-2 Superspher 
60 RP Select B guard column. The mobile phase consisted of 50 mM aqueous 
ammonium formate adjusted to pH 3.5 with formic acid (eluent A) and acetonitrile 
(eluent B). Before use, the mobile phases were degassed for 30 min in an ultrasonic 
bath. During use, the mobile phase was degassed by the corresponding integrated 
degasser. Before starting analysis, the HPLC systems were equilibrated for 10 min with 
a mixture of 90 % of eluent A and 10 % of eluent B. The gradient and the flow rate were 
programmed as follows: 0.00-2.00 min 10% B (flow: 0.4 ml/min), 2.01-5.00 min gradient 
increase to 80% B (flow: 0.6 ml/min), 5.01-7.00 min 80% B (flow: 0.60 ml/min) 7.01-
10.00 min 10% B (flow: 0.4 ml/min) for re-equilibration of the HPLC column. The column 
oven was set at 25°C.  
 
2.4.4.3 Single stage and Tandem MS Conditions  
For single stage MS, the following APCI inlet conditions were selected: drying gas, 
nitrogen (12 l/min, 350°C) and nebulizer gas, nitrogen (25 psi; 172.5 kPa); capillary 
voltage, 4000 V; vaporizer temperature, 400°C; corona current, 5.0 µA. The MS was 
operated in positive scan mode with a scan range from m/z 50 to 800 on MSD 1 for 
screening and identification, and in SIM mode on MSD 2 for quantification. For 
quantification, the SIM mode at 100 and 200 V fragmentor voltage with different gain 
values was used. The settings are given in Table 2.2. Tuning of the MS was performed 
with the help of the autotune feature of the LC-MS ChemStation software (rev. A.08.03) 
using the APCI acetonitrile solution tuning mix supplied by the manufacturer. 
2.4 Apparatus and Conditions 29 
 
 
 
2.4.4.2 LC Conditions  
The following LC conditions were identical in both systems. Gradient elution was 
performed on a Merck LiChroCART column (125 x 2 mm internal diameter) with 
Superspher60 RP Select B as stationary phase and a LiChroCART 10-2 Superspher 
60 RP Select B guard column. The mobile phase consisted of 50 mM aqueous 
ammonium formate adjusted to pH 3.5 with formic acid (eluent A) and acetonitrile 
(eluent B). Before use, the mobile phases were degassed for 30 min in an ultrasonic 
bath. During use, the mobile phase was degassed by the corresponding integrated 
degasser. Before starting analysis, the HPLC systems were equilibrated for 10 min with 
a mixture of 90 % of eluent A and 10 % of eluent B. The gradient and the flow rate were 
programmed as follows: 0.00-2.00 min 10% B (flow: 0.4 ml/min), 2.01-5.00 min gradient 
increase to 80% B (flow: 0.6 ml/min), 5.01-7.00 min 80% B (flow: 0.60 ml/min) 7.01-
10.00 min 10% B (flow: 0.4 ml/min) for re-equilibration of the HPLC column. The column 
oven was set at 25°C.  
 
2.4.4.3 Single stage and Tandem MS Conditions  
For single stage MS, the following APCI inlet conditions were selected: drying gas, 
nitrogen (12 l/min, 350°C) and nebulizer gas, nitrogen (25 psi; 172.5 kPa); capillary 
voltage, 4000 V; vaporizer temperature, 400°C; corona current, 5.0 µA. The MS was 
operated in positive scan mode with a scan range from m/z 50 to 800 on MSD 1 for 
screening and identification, and in SIM mode on MSD 2 for quantification. For 
quantification, the SIM mode at 100 and 200 V fragmentor voltage with different gain 
values was used. The settings are given in Table 2.2. Tuning of the MS was performed 
with the help of the autotune feature of the LC-MS ChemStation software (rev. A.08.03) 
using the APCI acetonitrile solution tuning mix supplied by the manufacturer. 
30 2 Experimental procedures 
 
 
 
Table 2.2. Analytes, monitored ions and parameter settings used in LC-APCI-MS 
 
Mass 
Range, 
m/z 
Fragmentor  
Voltage, V 
Gain  MSD 1 
(Full Scan) 
50-800 100 50  
Analyte Ion, m/z Fragmentor  
Voltage, V 
Gain Dwell time, 
ms 
Aconitine 646 100 5.0 28 
Atropine 290 100 5.0 28 
Colchicine 400 100 5.0 28 
Coniine 128 100 1.0 39 
Cotinine 177 100 1.0 39 
Cytisine 191 100 1.0 39 
Nicotine 163 100 1.0 39 
Physostigmine 276 100 5.0 28 
Scopolamine 304 100 5.0 28 
Cotine-d3 180 100 1.0 39 
Benzoylecgonine-d3 293 200 5.0 28 
MSD 2  
(SIM) 
Trimipramine-d3 298 200 5.0 28 
 
For tandem MS, the following ESI inlet conditions were selected: gas 1, nitrogen (45 psi; 
310.3 kPa); gas 2, nitrogen (90 psi; 620.5 kPa); ion spray voltage, 5500 V; ion source 
temperature, 630°C; curtain gas, nitrogen (30 psi; 206.8 kPa). The MS was operated in 
MRM mode with the following settings: collision gas was set at medium, the dwell time 
was set at 50 ms. All other settings were analyte specific and were determined using 
Analyst® software in Quantitative Optimization mode. The transitions used are given in 
Table 2.3. The method was checked for cross-talk by injection of the single analytes. Q1 
and Q3 were operated in Unit resolution. 
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Table 2.3. Analytes, MRM transitions and parameter settings including declustering potential (DP), 
entrance potential (ENP), collision cell entrance potential (CEP), collision energy (CE), and collision cell 
exit potential (CXP) used in LC-ESI-MS/MS. Target transitions are marked with (t), qualifier transitions 
marked with (q). 
 
Analyte Q 1 Mass, u Q 3 Mass, u DP, V ENP, V CEP, V CE, eV CXP, V
105.1 (t) 66 9.5 26 93 4 
586.4 (q) 66 9.5 26 45 4 
Aconitine 646.52 
368.2 (q) 66 9.5 26 55 6 
124.4 (t) 51 5.5 14 33 4 
93.1 (q) 51 5.5 14 43 4 
Atropine 290.31 
91.1 (q) 51 5.5 14 55 4 
152.2 (t) 51 8.5 24 129 4 
358.2 (q) 51 8.5 24 29 4 
Colchicine 400.31 
165.2 (q) 51 8.5 24 103 4 
69.1 (t) 31 9.0 10 23 2 
55.1 (q) 31 9.0 10 31 4 
Coniine 128.19 
83.1 (q) 31 9.0 10 21 4 
80.2 (t) 41 5.0 12 35 4 
98.1 (q) 41 5.0 12 33 4 
Cotinine 177.19 
53.0 (q) 41 5.0 12 67 4 
148.2 (t) 51 5.0 14 27 4 
80.1 (q) 51 5.0 14 51 2 
Cytisine 191.21 
91.3 (q) 51 5.0 14 55 2 
132.1 (t) 31 3.5 12 21 4 
117.2 (q) 31 3.5 12 35 4 
Nicotine 163.19 
130.2 (q) 31 3.5 12 25 4 
162.3 (t) 26 4.0 28 29 4 
219.3 (q) 26 4.0 28 17 4 
Physostigmine 276.27 
147.2 (q) 26 4.0 28 47 4 
138.3 (t) 46 5.0 16 27 4 Scopolamine 
 
304.27 
 103.2 (q) 46 5.0 16 53 4 
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Scopolamine 304.27 156.3 (q) 46 5.0 16 23 4 
171.2 (t) 46 4.5 18 29 4 
105.0 (q) 46 4.5 18 47 4 
Benzoylecgonine-d3 293.29 
76.8 (q) 46 4.5 18 65 4 
80.0 (t) 51 6.5 12 39 4 
101.0 (q) 51 6.5 12 35 4 
Cotinine-d3 180.19 
53.0 (q) 51 6.5 12 31 4 
61.1 (t) 41 5.5 19 53 6 
103.1 (q) 41 5.5 19 27 4 
Trimipramine-d3 298.28 
 
193.1 (q) 41 5.5 19 59 4 
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2.5 VALIDATION OF THE DESCRIBED METHODS 
2.5.1 Laxatives 
 
2.5.1.1 Limit of Detection Experiments 
Urine samples (2 ml) were spiked with decreasing concentrations of analytes and 
analyzed as described above. The lowest concentrations at which the analytes could 
still be successfully identified by library search and for which S/N ≥ 3 were obtained for 
at least three characteristic fragment ions per analyte were the estimated LODs of the 
procedure.  
 
2.5.1.2 Recovery Experiments 
Aliquots (2 ml) of urine (n = 6) were spiked to 50 ng/ml with bisacodyl diphenol, 
phenolphthalein and to 125 ng/ml with rhein. These samples were analyzed as 
described above (see 2.3.1). The peak areas of the derivatized analytes obtained from 
these samples were compared with the corresponding peak areas obtained from 
solutions of bisacodyl diphenol-2ME, phenolphthalein-2ME (2 000 ng/ml, each) and 
rhein-3ME (5 000 ng/ml) in ethyl acetate (concentrations correspond to 100% recovery).  
 
2.5.1.3 Stability Experiments 
For estimation of the stability of the analytes in buffer solution, 10 ml of urine spiked with 
100 µg/ml of each analyte (bisacodyl diphenol, phenolphthalein, rhein) was incubated 
with 10 ml extraction buffer at room temperature. At time points 0, 30, 120, 240, and 
480 min 4 ml-aliquots of the solution were taken and extractive methylation was 
performed as described above (2.3.1 Sample Preparation of Laxatives). 
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2.5 VALIDATION OF THE DESCRIBED METHODS 
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2.5.2 Herbal Phenalkylamines 
 
2.5.2.1 Preparation of Stock Solutions, Calibration Standards, and Control Samples 
Stock solutions of each analyte were prepared at a concentration of 1 mg/ml by 
separate weighings using eluent A as solvent. Working solutions of each analyte were 
prepared by independent dilution from each stock solution at the following 
concentrations: 0.001, 0.01, and 0.1 mg/ml. The calibration standards were prepared 
using pooled blank plasma and spiking solutions prepared from the working solutions as 
mixtures of the ten analytes in eluent A at concentrations ten times higher than the 
corresponding calibration standards. The quality control samples (concentrations as 
given in chapter 2.5.2.4) were prepared using pooled blank plasma and independently 
prepared mixtures of the ten analytes at concentrations hundred times higher than the 
concentrations of the corresponding quality control samples. All solutions were stored at 
4°C. 
 
2.5.2.2 Selectivity 
Ten blank plasma samples from different sources were analyzed and checked for peaks 
interfering with the detection of the analytes or the IS. In addition, to check for possible 
interferences from other common drugs and/or their metabolites, plasma samples 
routinely submitted to our laboratory for TDM or toxicological analysis were analyzed by 
the described procedure. The plasma samples did not contain any of the analytes as 
checked by comprehensive screening of the corresponding urine samples. 
 
2.5.2.3 Linearity 
Aliquots of blank plasma (1 ml) were spiked with 0.1 ml of the corresponding spiking 
solutions and 0.1 ml of IS solution to obtain calibration standards with concentrations of 
10, 20, 100, 250, 500, 750, 1000 ng/ml. Replicates (n = 6) at each concentration level 
were analyzed as described above. The regression line was calculated using a 
weighted [1/(concentration)2] least-squares regression model. A weighted second-order 
model with the same weighting factors was also calculated. Daily calibration curves 
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using the same concentrations (single measurements per level) were prepared with 
each batch of validation and authentic samples. 
 
2.5.2.4 Accuracy and Precision 
Qualitiy control (QC) samples were prepared at five concentration levels, namely near 
the lower limit of quantification (LLOQ) at 10 ng/ml (LQC), 20 ng/ml (LOW), 500 ng/ml 
(MED), 800 ng/ml (HIGH), and above the calibration range at 4000 ng/ml (ACR). They 
were analyzed according to the procedure described above in duplicate on each of eight 
days. The concentrations of the analytes in the quality control samples were calculated 
via the daily calibration curves. Accuracy was calculated for each analyte in terms of 
bias as the percent deviation of the mean of all calculated concentration values at a 
specific level from the respective nominal concentration. Precision data (given as 
relative standard deviations) for within-day (repeatability), and time-different 
intermediate precision (combination of within and between day effects) of the method 
were calculated according to references135,136 using one-way analysis of variance 
(ANOVA) with the grouping-variable "day". The acceptance intervals of within-day 
(repeatability) and intermediate precision were ≤ 15% RSD (≤ 20% RSD at LLOQ) and 
for bias ± 15% (± 20% at the LLOQ) of the nominal values.137 
 
2.5.2.5 Processed Sample Stability 
For estimation of stability of processed samples under the conditions of LC-MS/MS 
analysis, LOW and HIGH quality control samples (n = 10 each) were extracted as 
described above. The resulting extracts at each concentration level were pooled. 
Aliquots of these pooled extracts at each concentration level were transferred to 
autosampler vials and injected under the conditions of a regular analytical run at time 
intervals of 2 h. Stability of the extracted analytes was tested by regression analysis 
plotting absolute peak areas of each analyte at each concentration versus injection 
time. Instability of processed samples would be indicated by a negative slope 
significantly different from zero (p ≤ 0.05).138 
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2.5.2.6 Freeze/Thaw Stability and Bench Top Stability 
For evaluation of freeze/thaw stability, quality control samples (LOW and HIGH) were 
analyzed prior to (control samples, n = 6 each) and after three freeze/thaw cycles 
(stability samples, n = 6 each). For each freeze/thaw cycle, the samples were frozen at 
-20°C for 21 h, thawed and kept at ambient temperature for 3 h. The experiments were 
carried out together with the accuracy and precision experiments and the 
concentrations of the control and stability samples were calculated via daily calibration 
curves. Stability was tested against an acceptance interval of 90-110% for the ratio of 
the means (stability samples vs. control samples) and an acceptance interval of 80-
120% from the control samples’ mean for the 90% confidence interval (CI) of stability 
samples.138 
 
2.5.2.7 Long-term Stability 
The experimental design and procedure for evaluation of long term stability were similar 
to those used for freeze/thaw stability. Analyte stability for long-term storage was tested 
by analyzing spiked samples at two concentrations of the analytes (LOW/HIGH) before 
(control samples, n = 6 each) and after storage for one month at -20 °C (stability 
samples, n = 6 each).  
 
2.5.2.8 Lower Limits of Quantification 
The LLOQ in the MRM mode was defined as the lowest point of the calibration curve 
(concentration 10 ng/ml) and fulfilled the requirement of LLOQ, signal to noise ratio of 
10:1. The noise data from the assay of blank matrices was taken from the selectivity 
experiments. Furthermore, the accuracy and precision data of the LQC sample were 
compared with the criteria for the parameters at the LLOQ established by Shah et al.137 
(accuracy within ≤ 20% of the nominal value and a RSD < 20%). The LOD was not 
systematically evaluated. 
 
2.5.2.9 Extraction Efficiencies, Matrix Effects, and Process Efficiencies 
Extraction efficiencies, matrix effect, and process efficiencies were estimated in a post-
extraction addition approach as proposed in references.139,140 Three sets of samples 
were prepared at low and high concentrations. Samples in set 1 consisted of neat 
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standards containing the analytes at concentrations of 200 ng/ml and 8000 ng/ml in 
eluent A, respectively. For preparation of the samples in set 2, blank plasma samples 
from five different sources (1 ml, each) were first extracted as described above. Then, 
the dry residues were reconstituted in 100 µl of eluent A containing the analytes at 
concentrations of 200 ng/ml and 8000 ng/ml, respectively. For preparation of the 
samples in set 3, blank plasma samples (1 ml) from the same sources as those in set 2 
were spiked with 100 µl of eluent A containing the analytes at concentrations of 200 
ng/ml and 8000 ng/ml, respectively. Thereafter, they were extracted as described above 
and the dry residues were reconstituted in 100 µl of eluent A. 
Extraction efficiencies were estimated by comparison of the peak areas from the 
samples from set 3 to those from the corresponding samples of set 2 and reported in %. 
Matrix effects were estimated by comparison of the peak areas from the samples from 
set 2 to those from the corresponding samples of set 1 and reported in %. Hence, 
values below 100% indicate ion suppression while values above 100% indicate ion 
enhancement. Finally, process efficiencies (combination of extraction efficiencies and 
matrix effects) were estimated by comparison of the peak areas from the samples from 
set 3 to those from the corresponding samples of set 1 and also reported in %.  
 
2.5.2.10 Proof of Applicability 
Applicability experiments were carried out using plasma samples from healthy 
volunteers taken one hour after application of 10 g of an aqueous extract of Herba 
Ephedra (common dosage), 30 mg of pseudoephedrine (contained in Aspirin 
complex®), or 6.2 mg of ephedrine (contained in Wick MediNait®) after informed consent 
according to the declaration of Helsinki.  
 
2.5.3 Toxic Alkaloids 
For comparison of the two apparatus, the following validation experiments were 
performed using identical plasma extracts. After extraction of the plasma samples for 
validation, the extracts were first injected into the single stage MS, and directly after into 
the tandem MS. 
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samples from set 3 to those from the corresponding samples of set 2 and reported in %. 
Matrix effects were estimated by comparison of the peak areas from the samples from 
set 2 to those from the corresponding samples of set 1 and reported in %. Hence, 
values below 100% indicate ion suppression while values above 100% indicate ion 
enhancement. Finally, process efficiencies (combination of extraction efficiencies and 
matrix effects) were estimated by comparison of the peak areas from the samples from 
set 3 to those from the corresponding samples of set 1 and also reported in %.  
 
2.5.2.10 Proof of Applicability 
Applicability experiments were carried out using plasma samples from healthy 
volunteers taken one hour after application of 10 g of an aqueous extract of Herba 
Ephedra (common dosage), 30 mg of pseudoephedrine (contained in Aspirin 
complex®), or 6.2 mg of ephedrine (contained in Wick MediNait®) after informed consent 
according to the declaration of Helsinki.  
 
2.5.3 Toxic Alkaloids 
For comparison of the two apparatus, the following validation experiments were 
performed using identical plasma extracts. After extraction of the plasma samples for 
validation, the extracts were first injected into the single stage MS, and directly after into 
the tandem MS. 
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2.5.3.1 Preparation of Stock Solutions, Calibration Standards, and Control Samples 
Stock solutions of each analyte were prepared at a concentration of 1 mg/ml by 
separate weighings using eluent A as solvent. Working solutions of each analyte were 
prepared by independent dilution from each stock solution at the following 
concentrations: 0.001, 0.01, and 0.1 mg/ml. The calibration standards were prepared 
using pooled blank plasma and spiking solutions prepared from the working solutions as 
mixtures of the nine analytes in eluent A at concentrations ten times higher than the 
corresponding calibration standards. The quality control samples (concentrations as 
given in chapter 2.5.3.4) were prepared using pooled blank plasma and independently 
prepared mixtures of the nine analytes at concentrations hundred times higher than the 
concentrations of the corresponding quality control samples. All solutions were stored at 
4°C.  
 
2.5.3.2 Selectivity 
Ten blank plasma samples from different sources were analyzed using both apparatus 
and checked for peaks interfering with the detection of the analytes or the IS. A zero 
sample (blank sample + IS) was analyzed to check for absence of analyte ions in the 
respective peaks of the IS.  
 
2.5.3.3 Linearity 
Aliquots of blank plasma (1 ml) were spiked with 0.1 ml of the corresponding spiking 
solutions and 0.1 ml of IS solution to obtain calibration standards with concentrations of 
1, 50, 100, 250, 500, 750, 1000 ng/ml of cotinine, coniine, cytisine and nicotine, and 
concentrations of 0.1, 5, 10, 25, 50, 75, 100 ng/ml of aconitine, atropine, colchicine, 
scopolamine, and physostigmine. Replicates (n = 6) at each concentration level were 
analyzed as described above. Using single stage MS, the lowest concentration level 
could not be determined due to lower sensitivity of the apparatus. The regression line 
was calculated using a weighted [1/(concentration)2] least-squares regression model. A 
weighted second-order model with the same weighting factors was also calculated to 
check for possible non-linearity. Daily linear calibration curves using the same 
concentrations (single measurements per level) were prepared with each batch of 
validation and authentic samples. 
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2.5.3.4 Accuracy and Precision 
QC samples were prepared at three concentration levels. The concentrations were as 
follows: 100 ng/ml (LOW), 500 ng/ml (MED), and 800 ng/ml (HIGH) for coniine, cotinine, 
cytisine, and nicotine and 10 ng/ml (LOW), 50 ng/ml (MED), and 80 ng/ml (HIGH) for 
aconitine, atropine, colchicine, physostigmine, and scopolamine. They were analyzed 
using both apparatus according to the procedure described above in duplicate on each 
of eight days. The concentrations of the analytes in the quality control samples were 
calculated via the daily calibration curves. Accuracy was calculated for each analyte in 
terms of bias as the percent deviation of the mean of all calculated concentration values 
at a specific level from the respective nominal concentration. Precision data (given as 
relative standard deviations) for within-day (repeatability), and time-different 
intermediate precision (combination of within and between day effects) of the method 
were calculated according to references135,136 using one-way ANOVA with the grouping-
variable "day". The acceptance intervals of within-day (repeatability) and intermediate 
precision were ≤ 15% RSD and for bias ± 15% of the nominal values.137 
 
2.5.3.5 Processed Sample Stability 
For estimation of stability of processed samples under the conditions of single stage MS 
or tandem MS analysis, LOW and HIGH quality control samples (n = 10 each) were 
extracted as described above. The resulting extracts at each concentration level were 
pooled. Aliquots of these pooled extracts at each concentration level were transferred to 
autosampler vials and injected under the conditions of a regular analytical run of the 
corresponding apparatus at time intervals of 2 h. Stability of the extracted analytes was 
tested by regression analysis plotting absolute peak areas of each analyte at each 
concentration versus injection time. Instability of processed samples would be indicated 
by a negative slope significantly different from zero (p ≤ 0.05).138 
 
2.5.3.6 Freeze/Thaw and Bench Top Stability 
For evaluation of freeze/thaw stability, quality control samples (LOW and HIGH) were 
analyzed using both apparatus prior to (control samples, n = 6 each) and after three 
freeze/thaw cycles (stability samples, n = 6 each). For each freeze/thaw cycle, the 
samples were frozen at -20°C for 21 h, thawed and kept at ambient temperature for 3 h. 
The experiments were carried out together with the accuracy and precision experiments 
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and the concentrations of the control and stability samples were calculated via daily 
calibration curves. Stability was tested against an acceptance interval of 90-110% for 
the ratio of the means (stability samples vs. control samples) and an acceptance 
interval of 80-120% from the control samples’ mean for the 90% CI of stability 
samples.138 
 
2.5.3.7 Long-term Stability 
The experimental design and procedure for evaluation of long term stability were similar 
to those used for freeze/thaw stability. Analyte stability for long-term storage was tested 
by analyzing spiked samples at two concentrations of the analytes (LOW/HIGH) before 
(control samples, n = 6 each) and after storage for one month at -20 °C (stability 
samples, n = 6 each).  
 
2.5.3.8 Lower Limits of Quanification and Limit of Detection 
The LLOQ in the SIM mode for single stage MS or the MRM mode for tandem MS was 
defined as the lowest point of the calibration curve (concentrations of 50 ng/ml, and 5 
ng/ml respectively for single stage MS and concentrations of 1 ng/ml, and 0.1 ng/ml 
respectively for tandem MS) and fulfilled the requirement of LLOQ, signal to noise ratio 
of 10:1. The noise data from the assays of blank matrices were taken from the 
selectivity experiments. Plasma samples (1 ml) were spiked with decreasing 
concentrations of analytes and analyzed as described above. The LODs of the 
corresponding procedures were defined as the lowest concentrations at which 
identification was still possible by library search for single stage MS or S/N ≥ 3 were 
obtained for all monitored ions in the MRM mode.  
 
2.5.3.9 Extraction Efficiencies, Matrix Effects, and Process Effieciencies 
Extraction efficiencies, matrix effects, and process efficiencies were estimated in a post-
extraction addition approach as proposed in references.139,140 Three sets of samples 
were prepared at LOW and HIGH concentrations. Samples in set 1 consisted of neat 
standards containing the analytes at concentrations of 1000 ng/ml and 8000 ng/ml for 
coniine, cotinine, cytisine, and nicotine, as well as 100 ng/ml and 800 ng/ml for 
aconitine, atropine, colchicine, physostigmine, and scopolamine in eluent A, 
respectively. For preparation of the samples in set 2, blank plasma samples from five 
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different sources (1 ml, each) were first extracted as described above. Then, the dry 
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3 RESULTS AND DISCUSSION 
3.1 LAXATIVES 
3.1.1 Sample Preparation 
During preliminary studies, bisacodyl diphenol, phenolphthalein and rhein and/or their 
metabolites were found to be excreted in urine partly in conjugated form. Comparison of 
the peak areas of these analytes in authentic urine samples prepared with and without 
enzymatic conjugate cleavage showed that the extent of conjugation was about 50% for 
rhein and about 90% for bisacodyl diphenol and phenolphthalein. A further 
differentiation in glucuronides and sulfates was not possible from these data because a 
mixture of glucuronidase and arylsulfatase had been used for enzymatic hydrolysis. 
These results showed that cleavage of conjugates was necessary before extraction to 
increase sensitivity. In previously published procedures, acid hydrolysis had been used 
for this purpose.62,68 The cleavage rate of both hydrolysis procedures was similar. 
However, it is known that certain compounds may be altered or completely destroyed 
during acid hydrolysis. Among these are some which can also be analyzed using 
extractive methylation, e.g. diclofenac,73 buprenorphine,141 and some diuretics.142 
Because such compounds may also be present in authentic samples and because the 
described procedure should also be useful for STA, more time consuming but gentle 
enzymatic hydrolysis was preferred.  
Extractive alkylation (methylation) has proved to be suitable for analysis of different 
classes of more or less acidic compounds.70-73,141,143,144 It is based on the principle of 
phase transfer catalysis. The analytes were extracted as ion pairs, with the phase-
transfer catalyst at pH 12, into the organic phase. Reaching the organic phase the 
phase-transfer catalyst could easily be solvated because of its lipophilic hexyl groups. 
The poor solvatization of the anionic analytes leads to high reactivity against the 
methylation reagent methyl iodide. Part of the phase-transfer catalyst could also reach 
the organic phase as an ion pair with the iodide anion formed during the methylation 
reaction or with anions of the urine matrix. Part of these THA salts remained in the 
organic phase, so they had to be removed for maintaining the GC column´s separation 
power and to exclude interactions with analytes in the GC injection port. SPE with diol 
sorbent had successfully been used to remove THA salts from the organic phase,70-73 
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whereas the major part of the analytes passed through the column without being 
adsorbed. The part of the analytes which had also been adsorbed on the diol sorbent 
were selectively eluted with diethyl ether/ethyl acetate (95:5, v/v) to increase recovery, 
while THA salts remained adsorbed on the diol sorbent under these conditions.73 Major 
advantages of the diol columns over those described by Lisi et al.143 are their 
commercial availability and easy handling.70-73 
3.1.2 GC-MS Analysis 
The laxatives and/or their metabolites were separated by GC and identified by EI MS 
after enzymatic hydrolysis and extractive methylation. Fig. 3.1 shows the EI mass 
spectra, the proposed structures and the retention indices (RIs) of the methylated 
compounds or their metabolites. The RIs provide preliminary indications and may be 
useful to gas chromatographers without a GC-MS facility. They were recorded during 
the GC-MS procedure and calculated in correlation with the Kovats' indices145 of the 
components of a standard solution of typical drugs which is measured daily for testing 
the GC-MS performance.146 The reproducibility of retention indices measured on 
capillary columns was better using a mixture of drugs than that of the homologous 
hydrocarbons recommended by Kovats.145  
The presence of the laxatives and/or their metabolites was screened for via 
characteristic fragment ions. User defined macros extracting these fragment ions from 
the total ion current were used to facilitate this procedure. For all analytes, the base 
peak and an additional qualifier ion were used for screening: m/z 305, 290 for bisacodyl 
diphenol-2ME (mass spectrum no. 1 in Fig. 3.1), m/z 335 and 320 for bismethylated 
methoxy-bisacodyl diphenol (mass spectrum no. 2 in Fig. 3.1), m/z 365 and 350 for 
bismethylated bis-methoxy-bisacodyl diphenol (mass spectrum no. 3 in Fig. 3.1), and 
m/z 271 and 346 for phenolphthalein-2ME (mass spectrum no. 4 in Fig. 3.1), m/z 311 
and 326 for rhein-3ME (mass spectrum no. 5 in Fig. 3.1).  
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Fig. 3.1. EI mass spectra, gas chromatographic retention indices (RI), structures and predominant 
fragmentation patterns of stimulant laxatives and/or their metabolites after methylation. The ions used for 
mass chromatography are underlined.  
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Fig. 3.2 shows typical reconstructed mass chromatograms of an authentic urine sample 
after extractive methylation, which had been sent to our laboratory for toxicological 
analysis. Peak 1 indicates the presence of bisacodyl diphenol, peaks 2 and 3 indicate 
the presence of methoxy-bisacodyl diphenol and bis-methoxy-bisacodyl diphenol in the 
sample. For the latter two, differentiation of metabolic and extractive methylation was 
not possible with the described procedure. 
 
Fig. 3.2. Typical reconstructed mass chromatograms with the ions m/z 305, 290, 335, 320, 365, 350, 311, 
326, 271, and 346 of a urine extract after extractive methylation of a patient who has taken an unknown 
amount of bisacodyl or picosulfate and an anthraquinone containing plant extract. 
 
However, analysis of the same urine sample according to ref.68 showed that these two 
metabolites were indeed excreted in urine as conjugates of methoxy-bisacodyl diphenol 
and bis-methoxy-bisacodyl diphenol. Peak 5 indicates the presence of rhein. 
As illustrated in Fig. 3.3, the identity of positive peaks in corresponding mass 
chromatograms was confirmed by visual and computerized comparison of the 
underlying spectrum (here of peak 5 in Fig. 3.2) with reference spectra, which were 
already contained in the used reference library or had been recorded during the 
presented study. In order to avoid misinterpretation of the mass spectral analysis, 
proper use of the Pfleger/Maurer/Weber library147 is indispensable. The “@” sign 
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is a common metabolite of a series of active compounds in anthraquinone containing 
plant extracts. Therefore, detection of one or more of the common metabolites of 
bisacodyl and picosulfate does not allow to differentiate which of these two drugs have 
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3.1.3 Assay Validation 
Recoveries, analyte stability, and LODs were only determined for the analytes with the 
longest duration of detectability after ingestion of the above-mentioned laxatives. These 
are bisacodyl diphenol (main metabolite of bisacodyl and picosulfate), rhein (main 
metabolite of various active compounds in anthraquinone containing plant extracts) and 
phenolphthalein.62,68 Recovery experiments were carried out using SIM mode to allow 
more precise determination of peak areas. LOD experiments were carried out using full-
scan mode to allow estimation of LODs under routine conditions. The results for both 
parameters are given in Table 3.1. All three analytes showed reproducible recoveries as 
indicated by the low standard deviations. The lower recovery of rhein in comparison to 
the two other analytes could in part be explained by the instability of this analyte in 
buffer solution, even at room temperature.  
Table 3.1. Overall Recoveries with Coefficient of Variation and LOD (S/N= 3), 
determined in the SIM Mode 
 
Target Analyte Recovery LOD 
Bisacodyl diphenol 62.2 ± 7.35 % 10 ng/ml 
Phenolphthalein 89.5 ± 14.64 % 10 ng/ml 
Rhein 33.0 ± 4.22 % 25 ng/ml 
 
Fig. 3.4. shows the extent of degradation of the analytes in a urine sample incubated 
with buffer solution at room temperature. For all three analytes a significant decrease of 
peak areas could be observed for aliquots taken and worked up after increasing 
intervals of time. Degradation of rhein was especially pronounced and followed a 
mathematical model of monoexponential decay. These results show that samples have 
to be worked up immediately after addition of buffer solution to prevent considerable 
losses of analytes. At the elevated temperature of extractive methylation (50 °C) 
degradation can be expected to be even faster. Therefore, one might consider a 
reduction of shaking time during sample preparation. However, since recoveries were 
reproducible and LODs were satisfactory even for rhein, there was no reason to change 
the described procedure which is also routinely used for screening analysis of acidic 
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compounds in our laboratory.70-73 Finally, with the described procedure, rhein was still 
detectable in a urine sample of a healthy young volunteer taken 24 h after ingestion of 
the lowest therapeutic dose of senna extract. bisacodyl diphenol was still detectable in a 
urine sample of a volunteer collected 52 h after ingestion of the lowest therapeutic dose 
of sodium picosulfate.  
 
 
Fig. 3.4. Degradation of the analytes, expressed as peak areas in relation to the initial values, over time 
in a urine sample incubated with buffer solution at room temperature.  
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3.2 INGREDIENTS OF NUTMEG 
3.2.1 Identification of Metabolites of Elemicin, Myristicin and Safrole in Rat Urine 
The urinary metabolites of the nutmeg ingredients were separated by GC and identified 
by EI MS after enzymatic hydrolysis, extraction and acetylation. Fig. 3.5 A-C shows 
reconstructed mass chromatograms of acetylated rat urine extracts after administration 
of 100 mg/kg BM each of safrole (A), myristicin (B), or elemicin (C). The peak numbers 
correspond to the numbering in Fig. 3.6. The mass spectra underlying the numbered 
peaks were interpreted in correlation to those of the parent compound according to the 
rules described by e.g. McLafferty and Turecek131 and Smith and Busch.132 The 
corresponding EI mass spectra, the gas chromatographic RI, the concluded structures 
and postulated predominant fragmentation patterns of safrole, myristicin, elemicin, and 
their acetylated metabolites are shown in Fig. 3.6. After administration of safrole (mass 
spectrum no. 1), the following acetylated metabolites could be identified (the mass 
spectra numbers in Fig. 3.6 are given in brackets): 1-(3’-methoxy-4’-hydroxyphenyl)-
prop-2-ene (2), 1-(3’,4’-methylenedioxy-5’-hydroxyphenyl)-prop-2-ene (3), 1-(3’,4’-
dihydroxyphenyl)-prop-2-ene (4), 1-hydroxy-1-(3’,4’-methylenedioxyphenyl)-prop-2-ene 
(5), 1-(3’,4’-dihydroxy-5’-methoxyphenyl)-prop-2-ene (6), and 2,3-dihydroxy-1-(3’,4’-
methylenedioxyphenyl)-propane (7). After administration of myristicin (8), the following 
metabolites could be identified: 1-(3’,4’-methylenedioxy-5’-hydroxyphenyl)-prop-2-ene 
(3), 1-(3’,4’-dihydroxy-5’-methoxyphenyl)-prop-2-ene (6), 1-(3’,5’-dimethoxy-4’-
hydroxyphenyl)-prop-2-ene (9), 1-hydroxy-1-(3’,4’-methylenedioxy-5’-methoxy-phenyl)-
prop-2-ene (10), and 2,3-dihydroxy-1-(3’,4’-methylenedioxy-5’-methoxyphenyl)-propane 
(11). After administration of elemicin (12), the following metabolites could be identified: 
1-(3’,4’-dihydroxy-5’-methoxyphenyl)-prop-2-ene (6), 1-(3’,5’-dimethoxy-4’-
hydroxyphenyl)-prop-2-ene (9), 1-(3’,4’-dimethoxy-5’-hydroxyphenyl)-prop-2-ene (13), 1-
hydroxy-1-(3’,4’,5’-trimethoxyphenyl)-prop-2-ene (14), 2,3-dihydroxy-1-(3’,4’,5’-tri-
methoxyphenyl)-propane (15), and two isomers of 2,3-dihydroxy-1-(dimethoxy-
hydroxyphenyl)-propane (16 and 17). In none of the urine extracts, the corresponding 
amphetamine derivatives MMDA, TMA, or 3,4-methylenedioxyamphetamine (MDA), 
could be detected. No further metabolites of safrole, myristicin or elemicin could be 
detected in the acidic extracts after methylation and acetylation.  
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Fig. 3.5. Typical reconstructed mass chromatograms with the given ions of acetylated extracts of 
enzymatically hydrolyzed rat urine samples after administration of 100 mg/kg BM of safrole (A), myristicin 
(B), and elemicin (C). Part D: reconstructed mass chromatograms of an acetylated human urine extract 
after administration of an unknown dose of nutmeg. The peak numbers correspond to those used in Fig. 
3.6, Fig. 3.7, and Fig. 3.8. The merged chromatograms can be differentiated by their colors on a color 
screen.  
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screen.  
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Fig. 3.6. EI mass spectra, the gas chromatographic retention indices (RI), structures and predominant 
fragmentation patterns of safrole, myristicin, elemicin, and their metabolites after acetylation. The 
numbers of the spectra correspond to those in Fig. 3.5, Fig. 3.7, and Fig. 3.8.  
 
The position of the hydroxy or methoxy group in metabolites 2 and 9 could not be 
determined by means of GC-MS, but the given positions were assumed from the 
metabolic point of view since the methylation step is most probably catalyzed by the 
enzyme catechol-O-methyl transferase (COMT) which predominantly methylates in 3’ 
position. The position of the free hydroxy group in metabolite 13 was assumed because 
this metabolite had a retention time different form the isomeric metabolite 9, and 
because metabolite 13 was only found in the urine after administration of elemicin. In 
the two isomeric metabolites 16 and 17, the position of the ring hydroxy group could not 
further be elucidated because they were detected only after administration of elemicin. 
3.2.2 Identification of Metabolites of Elemicin, Myristicin and Safrole in Rat Urine 
Fig. 3.5 (D) shows reconstructed mass chromatograms of an acetylated human urine 
extract after administration of an unknown dose of nutmeg. The peak numbers 
correspond to the numbering in Fig. 3.6. Unnumbered peaks represent endogenous 
biomolecules. As can be seen, metabolites 4, 6, 9, 11, 16, and 17 could be identified 
also in human urine. While metabolite 4 could only be formed from safrole, metabolite 
11 only by myristicin, and metabolites 16 and 17 only by elemicin, metabolite 9 could be 
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3.2 Ingredients of Nutmeg 55 
 
 
formed from myristicin and elemicin and metabolite 6 from all studied nutmeg 
ingredients.  
 
3.2.3 Postulated Metabolic Pathways of Elemicin, Myristicin and Safrole in Rats 
and Humans 
Based on the metabolites identified as described above, the following metabolic 
pathways of safrole, myristicin and elemicin could be postulated as shown in Fig. 3.7 
(metabolites found in human urine are marked by "h"): for safrole, myristicin and 
elemicin, hydroxylation of the side chain to the corresponding 1-hydroxy metabolites 5, 
10, and 14, bis-hydroxylation of the side chain to the corresponding 2,3-
dihydroxy-metabolites 7, 11, and 15; for safrole and myristicin, demethylenation to the 
metabolites 4 and 6 followed by methylation to the metabolites 2 and 9; for elemicin, O-
demethylation at position 3’ and 4’ to metabolites 9 and 13 followed by side chain 
hydroxylation to the two isomers 16 and 17. Comparing the peak areas in Fig. 3.5 (A-C), 
demethylenation seems to be the main metabolic step for safrole and myristicin and 
side chain hydroxylation for elemicin. All metabolites were partly excreted as 
glucuronides and/or sulfates, since the peak areas were greater after enzymatic 
hydrolysis. 
 
Fig. 3.7. Proposed scheme for the metabolism of safrole (1), myristicin (8), and elemicin (12) in rat and 
humans. The metabolites marked with h were also detected in a human urine sample after nutmeg abuse. 
The numbers of compounds correspond to those in Fig. 3.5, Fig. 3.6, and Fig 3.8. 
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3.2.4 Monitoring of a Nutmeg Abuse or Intoxication using Systematic 
Toxicological Analysis 
The STA procedure is based on acid hydrolysis for very efficient and fast cleavage of 
conjugates.150 However, some compounds were altered or destroyed during 
hydrolysis.151,152 Therefore, one part of unhydrolyzed urine was added to the hydrolyzed 
aliquot before extraction. This modified sample preparation was a compromise between 
the necessity of a quick cleavage of conjugates and the detectability of compounds 
destroyed during acid hydrolysis. Although the modification of the STA procedure led to 
lower extract concentrations of compounds excreted in conjugated form, this modified 
procedure was sufficient, because of the high sensitivity of modern GC-MS 
apparatus.151,152  
  
Fig. 3.8. Typical reconstructed mass chromatograms with the given ions of acidic hydrolyzed and 
acetylated extracts of rat urine sample after administration of 500 mg/kg BM of nutmeg (A and B), and a 
human urine sample after nutmeg abuse (C). The peak numbers correspond to those used in Fig. 3.5-3.7. 
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The metabolites of safrole, myristicin, and elemicin were separated by GC and identified 
by EI MS after acid hydrolysis, extraction and acetylation within the STA.79-84 Mass 
chromatography with the following ions m/z 150, 165, 180, 194, 252, and 266 was used 
to indicate the presence of the metabolites of the main ingredients of the volative oil of 
nutmeg. Generation of the mass chromatograms could be started by clicking the 
corresponding pull down menu which executes the user defined macros. Fig. 3.8 (A and 
B) shows typical reconstructed mass chromatograms with the above-mentioned ions of 
an acetylated rat urine extract after application of nutmeg (500 mg/kg each) from 
different geographical sources. In part A, the peak area of metabolite 6, the main 
metabolite of myristicin, but also formed by safrole and elemicin, was about ten times 
higher than that of the others, while in part B, it was only about twice as high. This can 
be explained by the fact, that the content of myristicin may vary from source to source.22  
Part C shows typical reconstructed mass chromatograms with the above-mentioned 
ions of an acetylated human urine extract after suspected nutmeg abuse. The peak 
numbers correspond to the numbering in Fig. 3.5, Fig. 3.6, and Fig. 3.7. Unnumbered 
peaks represent endogenous biomolecules. The identity of peaks in the mass 
chromatograms was confirmed by computerized comparison of the underlying mass 
spectrum with reference spectra recorded during this study.134 The ions m/z 150 and 
164 were used for indication of the presence of the safrole metabolites 2 and 4, the ions 
m/z 165, 180 and 194 for the metabolites of myristicin 6, 9 and 11, and the ions m/z 252 
and 266 for the elemicin metabolites 15-17. In our experience, the RIs provide 
preliminary indications and may be useful to gas chromatographers without a GC-MS 
facility. In addition, they allow distinguishing between the different isomers.  
Therefore, they are also given in Fig. 3.6. The RIs were recorded during the GC-MS 
procedure and calculated in correlation with the Kovats' indices145 of the components of 
a standard solution of typical drugs which is measured daily for testing the GC-MS 
performance.146 The reproducibility of RIs measured on capillary columns was better 
using a mixture of drugs than that of the homologous hydrocarbons recommended by 
Kovats. Although interferences by biomolecules or further drugs cannot be entirely 
excluded, they are rather unlikely, because their mass spectra and/or their RIs should 
be different and included in the reference library134 used.  
Screening for safrole, myristicin, and elemicin themselves was not successful, because 
the substances could neither be detected in urine after administration of nutmeg nor 
after high doses of the three substances themselves. The STA procedure allowed 
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identification of the main metabolites of the nutmeg ingredients safrole, myristicin, and 
elemicin in rat and human urine after administration of a commonly abused dose thus 
allowing to monitor a nutmeg abuse and/or intoxication. These findings have been 
confirmed by Staack and Paul from the Institute of Forensic Toxicology, LMU Munich, 
Germany (personal communication, to be published elsewhere), who could also detect 
the described metabolites in urine of a nutmeg abuser using our STA procedure and the 
reference spectra shown in Fig3.6. The limit of detection could not be determined for 
these metabolites, because reference substances were not available. As already 
mentioned above, the postulated amphetamine derivatives MMDA, TMA, and MDA, 
could not be detected neither in rat, nor in human urine, although, as already mentioned 
above, amphetamine-derived designer drugs could be detected by STA with a detection 
limit of 5-50 ng/ml.85,86  
 
3.3 HERBAL PHENALKYLAMINES 
An LC-ESI-MS/MS assay was developed for selective detection as well as for accurate 
and precise quantification of nine herbal phenalkylamines and methcathinone in human 
plasma. It allows monitoring of an abuse or intoxication as well as differentiation of an 
intake of cold medications from herbal drug or methcathinone abuse in contrast to all 
procedures cited in the Introduction. In addition, the LLOQs were ten times lower than 
those of the other multi-analyte plasma procedures.26,94 The assay was validated 
according international guidelines.137,140,153,154 
 
3.3.1 Extraction Procedure 
In early development stages of the presented assay, it was intended to extract the ten 
analytes by our standard plasma mixed-mode SPE procedure,96,136,155,156 in which the 
analytes were isolated from 1 ml of plasma after dilution with 2 ml of water. This 
procedure had been reported to be versatile for the extraction of designer drugs, 
neuroleptics, and beta-blockers from plasma.96,136,155,156 However, during method 
development, it was recognized that the pH of spiked control samples increased by up 
to 0.75 after freezing and thawing. This caused a decrease in the extraction efficiency of 
all analytes but mescaline. At higher pH values, the relatively polar ephedrines are not 
retained by the reversed-phase part of the SPE sorbent and lacking protonation neither 
58 3 Results and Discussion 
 
 
identification of the main metabolites of the nutmeg ingredients safrole, myristicin, and 
elemicin in rat and human urine after administration of a commonly abused dose thus 
allowing to monitor a nutmeg abuse and/or intoxication. These findings have been 
confirmed by Staack and Paul from the Institute of Forensic Toxicology, LMU Munich, 
Germany (personal communication, to be published elsewhere), who could also detect 
the described metabolites in urine of a nutmeg abuser using our STA procedure and the 
reference spectra shown in Fig3.6. The limit of detection could not be determined for 
these metabolites, because reference substances were not available. As already 
mentioned above, the postulated amphetamine derivatives MMDA, TMA, and MDA, 
could not be detected neither in rat, nor in human urine, although, as already mentioned 
above, amphetamine-derived designer drugs could be detected by STA with a detection 
limit of 5-50 ng/ml.85,86  
 
3.3 HERBAL PHENALKYLAMINES 
An LC-ESI-MS/MS assay was developed for selective detection as well as for accurate 
and precise quantification of nine herbal phenalkylamines and methcathinone in human 
plasma. It allows monitoring of an abuse or intoxication as well as differentiation of an 
intake of cold medications from herbal drug or methcathinone abuse in contrast to all 
procedures cited in the Introduction. In addition, the LLOQs were ten times lower than 
those of the other multi-analyte plasma procedures.26,94 The assay was validated 
according international guidelines.137,140,153,154 
 
3.3.1 Extraction Procedure 
In early development stages of the presented assay, it was intended to extract the ten 
analytes by our standard plasma mixed-mode SPE procedure,96,136,155,156 in which the 
analytes were isolated from 1 ml of plasma after dilution with 2 ml of water. This 
procedure had been reported to be versatile for the extraction of designer drugs, 
neuroleptics, and beta-blockers from plasma.96,136,155,156 However, during method 
development, it was recognized that the pH of spiked control samples increased by up 
to 0.75 after freezing and thawing. This caused a decrease in the extraction efficiency of 
all analytes but mescaline. At higher pH values, the relatively polar ephedrines are not 
retained by the reversed-phase part of the SPE sorbent and lacking protonation neither 
58 3 Results and Discussion 
 
 
identification of the main metabolites of the nutmeg ingredients safrole, myristicin, and 
elemicin in rat and human urine after administration of a commonly abused dose thus 
allowing to monitor a nutmeg abuse and/or intoxication. These findings have been 
confirmed by Staack and Paul from the Institute of Forensic Toxicology, LMU Munich, 
Germany (personal communication, to be published elsewhere), who could also detect 
the described metabolites in urine of a nutmeg abuser using our STA procedure and the 
reference spectra shown in Fig3.6. The limit of detection could not be determined for 
these metabolites, because reference substances were not available. As already 
mentioned above, the postulated amphetamine derivatives MMDA, TMA, and MDA, 
could not be detected neither in rat, nor in human urine, although, as already mentioned 
above, amphetamine-derived designer drugs could be detected by STA with a detection 
limit of 5-50 ng/ml.85,86  
 
3.3 HERBAL PHENALKYLAMINES 
An LC-ESI-MS/MS assay was developed for selective detection as well as for accurate 
and precise quantification of nine herbal phenalkylamines and methcathinone in human 
plasma. It allows monitoring of an abuse or intoxication as well as differentiation of an 
intake of cold medications from herbal drug or methcathinone abuse in contrast to all 
procedures cited in the Introduction. In addition, the LLOQs were ten times lower than 
those of the other multi-analyte plasma procedures.26,94 The assay was validated 
according international guidelines.137,140,153,154 
 
3.3.1 Extraction Procedure 
In early development stages of the presented assay, it was intended to extract the ten 
analytes by our standard plasma mixed-mode SPE procedure,96,136,155,156 in which the 
analytes were isolated from 1 ml of plasma after dilution with 2 ml of water. This 
procedure had been reported to be versatile for the extraction of designer drugs, 
neuroleptics, and beta-blockers from plasma.96,136,155,156 However, during method 
development, it was recognized that the pH of spiked control samples increased by up 
to 0.75 after freezing and thawing. This caused a decrease in the extraction efficiency of 
all analytes but mescaline. At higher pH values, the relatively polar ephedrines are not 
retained by the reversed-phase part of the SPE sorbent and lacking protonation neither 
58 3 Results and Discussion 
 
 
identification of the main metabolites of the nutmeg ingredients safrole, myristicin, and 
elemicin in rat and human urine after administration of a commonly abused dose thus 
allowing to monitor a nutmeg abuse and/or intoxication. These findings have been 
confirmed by Staack and Paul from the Institute of Forensic Toxicology, LMU Munich, 
Germany (personal communication, to be published elsewhere), who could also detect 
the described metabolites in urine of a nutmeg abuser using our STA procedure and the 
reference spectra shown in Fig3.6. The limit of detection could not be determined for 
these metabolites, because reference substances were not available. As already 
mentioned above, the postulated amphetamine derivatives MMDA, TMA, and MDA, 
could not be detected neither in rat, nor in human urine, although, as already mentioned 
above, amphetamine-derived designer drugs could be detected by STA with a detection 
limit of 5-50 ng/ml.85,86  
 
3.3 HERBAL PHENALKYLAMINES 
An LC-ESI-MS/MS assay was developed for selective detection as well as for accurate 
and precise quantification of nine herbal phenalkylamines and methcathinone in human 
plasma. It allows monitoring of an abuse or intoxication as well as differentiation of an 
intake of cold medications from herbal drug or methcathinone abuse in contrast to all 
procedures cited in the Introduction. In addition, the LLOQs were ten times lower than 
those of the other multi-analyte plasma procedures.26,94 The assay was validated 
according international guidelines.137,140,153,154 
 
3.3.1 Extraction Procedure 
In early development stages of the presented assay, it was intended to extract the ten 
analytes by our standard plasma mixed-mode SPE procedure,96,136,155,156 in which the 
analytes were isolated from 1 ml of plasma after dilution with 2 ml of water. This 
procedure had been reported to be versatile for the extraction of designer drugs, 
neuroleptics, and beta-blockers from plasma.96,136,155,156 However, during method 
development, it was recognized that the pH of spiked control samples increased by up 
to 0.75 after freezing and thawing. This caused a decrease in the extraction efficiency of 
all analytes but mescaline. At higher pH values, the relatively polar ephedrines are not 
retained by the reversed-phase part of the SPE sorbent and lacking protonation neither 
3.3 Herbal Phenalkylamines 59 
 
 
by the ion exchange part. While mescaline also lacks protonation, it was retained well 
by the reversed-phase sorbent most probably due to its higher lipophilicity. Therefore, 
the plasma samples were diluted with acidic buffer instead of water. As shown in 
Table 3.2, the extraction efficiency values ranged from 45 to 93 %. In comparison of 
previously studied compounds, the extraction efficiencies are relatively low, but due to 
their reproducibility and the sufficient sensitivity of the LC-MS/MS assay, they were 
considered acceptable.  
Table 3.2. Extraction efficiency, matrix effect, and process efficiency of the LC-MS/MS assay for the 
studied analytes determined at concentrations of 20 ng/ml (LOW) and 800 ng/ml (HIGH) 
 
Extraction efficiency 
(mean ± SD, %) 
Matrix effect 
(mean ± SD, %) 
Process efficiency 
(mean ± SD, %) 
Analyte 
LOW  
(n = 5) 
HIGH  
(n = 5) 
LOW  
(n = 5) 
HIGH  
(n = 5) 
LOW  
(n = 5) 
HIGH  
(n = 5) 
Cathinone 92 ± 6.4 85 ± 7.9 93 ± 6.7 96 ± 4.5 85 ± 5.9 82 ± 7.6 
Ephedrine 85 ± 4.6 82 ± 5.4 87 ± 4.4 91 ± 3.5 74 ± 4.0 75 ± 5.0 
Methcathinone 84 ± 7.2 75 ± 8.5 102 ± 4.3 96 ± 4.4 85 ± 7.4 72 ± 8.2 
Methylephedrine 93 ± 5.9 80 ± 8.7 95 ± 4.9 96 ± 2.0 88 ± 5.6 76 ± 8.3 
Mescaline 84 ± 5.7 72 ± 9.6 103 ± 3.7 96 ± 4.0 86 ± 5.9 69 ± 9.2 
Methylpseudo-
ephedrine 
92 ± 5.8 72 ± 4.3 93 ± 7.0 100 ± 4.0 86 ± 5.4 72 ± 4.1 
Norephedrine 81 ± 9.1 81 ± 6.6 73 ± 3.4 88 ± 5.4 59 ± 6.7 72 ± 5.8 
Norpseudo-
ephedrine 
64 ± 10.3 78 ± 6.8 82 ± 13.3 73 ± 4.8 53 ± 8.5 57 ± 5.0 
Pseudoephedrine 80 ± 6.5 71 ± 6.7 93 ± 5.9 96 ± 5.7 75 ± 6.0 68 ± 6.5 
Synephrine 45 ± 5.0 55 ± 4.0 92 ± 9.5 94 ± 9.0 41 ± 4.6 52 ± 3.8 
 
3.3 Herbal Phenalkylamines 59 
 
 
by the ion exchange part. While mescaline also lacks protonation, it was retained well 
by the reversed-phase sorbent most probably due to its higher lipophilicity. Therefore, 
the plasma samples were diluted with acidic buffer instead of water. As shown in 
Table 3.2, the extraction efficiency values ranged from 45 to 93 %. In comparison of 
previously studied compounds, the extraction efficiencies are relatively low, but due to 
their reproducibility and the sufficient sensitivity of the LC-MS/MS assay, they were 
considered acceptable.  
Table 3.2. Extraction efficiency, matrix effect, and process efficiency of the LC-MS/MS assay for the 
studied analytes determined at concentrations of 20 ng/ml (LOW) and 800 ng/ml (HIGH) 
 
Extraction efficiency 
(mean ± SD, %) 
Matrix effect 
(mean ± SD, %) 
Process efficiency 
(mean ± SD, %) 
Analyte 
LOW  
(n = 5) 
HIGH  
(n = 5) 
LOW  
(n = 5) 
HIGH  
(n = 5) 
LOW  
(n = 5) 
HIGH  
(n = 5) 
Cathinone 92 ± 6.4 85 ± 7.9 93 ± 6.7 96 ± 4.5 85 ± 5.9 82 ± 7.6 
Ephedrine 85 ± 4.6 82 ± 5.4 87 ± 4.4 91 ± 3.5 74 ± 4.0 75 ± 5.0 
Methcathinone 84 ± 7.2 75 ± 8.5 102 ± 4.3 96 ± 4.4 85 ± 7.4 72 ± 8.2 
Methylephedrine 93 ± 5.9 80 ± 8.7 95 ± 4.9 96 ± 2.0 88 ± 5.6 76 ± 8.3 
Mescaline 84 ± 5.7 72 ± 9.6 103 ± 3.7 96 ± 4.0 86 ± 5.9 69 ± 9.2 
Methylpseudo-
ephedrine 
92 ± 5.8 72 ± 4.3 93 ± 7.0 100 ± 4.0 86 ± 5.4 72 ± 4.1 
Norephedrine 81 ± 9.1 81 ± 6.6 73 ± 3.4 88 ± 5.4 59 ± 6.7 72 ± 5.8 
Norpseudo-
ephedrine 
64 ± 10.3 78 ± 6.8 82 ± 13.3 73 ± 4.8 53 ± 8.5 57 ± 5.0 
Pseudoephedrine 80 ± 6.5 71 ± 6.7 93 ± 5.9 96 ± 5.7 75 ± 6.0 68 ± 6.5 
Synephrine 45 ± 5.0 55 ± 4.0 92 ± 9.5 94 ± 9.0 41 ± 4.6 52 ± 3.8 
 
3.3 Herbal Phenalkylamines 59 
 
 
by the ion exchange part. While mescaline also lacks protonation, it was retained well 
by the reversed-phase sorbent most probably due to its higher lipophilicity. Therefore, 
the plasma samples were diluted with acidic buffer instead of water. As shown in 
Table 3.2, the extraction efficiency values ranged from 45 to 93 %. In comparison of 
previously studied compounds, the extraction efficiencies are relatively low, but due to 
their reproducibility and the sufficient sensitivity of the LC-MS/MS assay, they were 
considered acceptable.  
Table 3.2. Extraction efficiency, matrix effect, and process efficiency of the LC-MS/MS assay for the 
studied analytes determined at concentrations of 20 ng/ml (LOW) and 800 ng/ml (HIGH) 
 
Extraction efficiency 
(mean ± SD, %) 
Matrix effect 
(mean ± SD, %) 
Process efficiency 
(mean ± SD, %) 
Analyte 
LOW  
(n = 5) 
HIGH  
(n = 5) 
LOW  
(n = 5) 
HIGH  
(n = 5) 
LOW  
(n = 5) 
HIGH  
(n = 5) 
Cathinone 92 ± 6.4 85 ± 7.9 93 ± 6.7 96 ± 4.5 85 ± 5.9 82 ± 7.6 
Ephedrine 85 ± 4.6 82 ± 5.4 87 ± 4.4 91 ± 3.5 74 ± 4.0 75 ± 5.0 
Methcathinone 84 ± 7.2 75 ± 8.5 102 ± 4.3 96 ± 4.4 85 ± 7.4 72 ± 8.2 
Methylephedrine 93 ± 5.9 80 ± 8.7 95 ± 4.9 96 ± 2.0 88 ± 5.6 76 ± 8.3 
Mescaline 84 ± 5.7 72 ± 9.6 103 ± 3.7 96 ± 4.0 86 ± 5.9 69 ± 9.2 
Methylpseudo-
ephedrine 
92 ± 5.8 72 ± 4.3 93 ± 7.0 100 ± 4.0 86 ± 5.4 72 ± 4.1 
Norephedrine 81 ± 9.1 81 ± 6.6 73 ± 3.4 88 ± 5.4 59 ± 6.7 72 ± 5.8 
Norpseudo-
ephedrine 
64 ± 10.3 78 ± 6.8 82 ± 13.3 73 ± 4.8 53 ± 8.5 57 ± 5.0 
Pseudoephedrine 80 ± 6.5 71 ± 6.7 93 ± 5.9 96 ± 5.7 75 ± 6.0 68 ± 6.5 
Synephrine 45 ± 5.0 55 ± 4.0 92 ± 9.5 94 ± 9.0 41 ± 4.6 52 ± 3.8 
 
3.3 Herbal Phenalkylamines 59 
 
 
by the ion exchange part. While mescaline also lacks protonation, it was retained well 
by the reversed-phase sorbent most probably due to its higher lipophilicity. Therefore, 
the plasma samples were diluted with acidic buffer instead of water. As shown in 
Table 3.2, the extraction efficiency values ranged from 45 to 93 %. In comparison of 
previously studied compounds, the extraction efficiencies are relatively low, but due to 
their reproducibility and the sufficient sensitivity of the LC-MS/MS assay, they were 
considered acceptable.  
Table 3.2. Extraction efficiency, matrix effect, and process efficiency of the LC-MS/MS assay for the 
studied analytes determined at concentrations of 20 ng/ml (LOW) and 800 ng/ml (HIGH) 
 
Extraction efficiency 
(mean ± SD, %) 
Matrix effect 
(mean ± SD, %) 
Process efficiency 
(mean ± SD, %) 
Analyte 
LOW  
(n = 5) 
HIGH  
(n = 5) 
LOW  
(n = 5) 
HIGH  
(n = 5) 
LOW  
(n = 5) 
HIGH  
(n = 5) 
Cathinone 92 ± 6.4 85 ± 7.9 93 ± 6.7 96 ± 4.5 85 ± 5.9 82 ± 7.6 
Ephedrine 85 ± 4.6 82 ± 5.4 87 ± 4.4 91 ± 3.5 74 ± 4.0 75 ± 5.0 
Methcathinone 84 ± 7.2 75 ± 8.5 102 ± 4.3 96 ± 4.4 85 ± 7.4 72 ± 8.2 
Methylephedrine 93 ± 5.9 80 ± 8.7 95 ± 4.9 96 ± 2.0 88 ± 5.6 76 ± 8.3 
Mescaline 84 ± 5.7 72 ± 9.6 103 ± 3.7 96 ± 4.0 86 ± 5.9 69 ± 9.2 
Methylpseudo-
ephedrine 
92 ± 5.8 72 ± 4.3 93 ± 7.0 100 ± 4.0 86 ± 5.4 72 ± 4.1 
Norephedrine 81 ± 9.1 81 ± 6.6 73 ± 3.4 88 ± 5.4 59 ± 6.7 72 ± 5.8 
Norpseudo-
ephedrine 
64 ± 10.3 78 ± 6.8 82 ± 13.3 73 ± 4.8 53 ± 8.5 57 ± 5.0 
Pseudoephedrine 80 ± 6.5 71 ± 6.7 93 ± 5.9 96 ± 5.7 75 ± 6.0 68 ± 6.5 
Synephrine 45 ± 5.0 55 ± 4.0 92 ± 9.5 94 ± 9.0 41 ± 4.6 52 ± 3.8 
 
60 3 Results and Discussion 
 
 
3.3.2 Detection and Quantification 
The ESI mode was preferred over the APCI mode, because it was found to be more 
sensitive in preliminary experiments and because no relevant matrix effects were 
observed as shown in Table 3.2. The highest matrix effect was observed for 
norephedrine, but this was sufficiently compensated by its deuterated IS, because 
accuracy and precision were acceptable.  
The presence of the drugs was successfully detected in the MRM mode by mass 
fragmentography using three MRM transitions for each substance. Transitions were 
selected and their settings were determined using a 1000 ng/ml solution of each analyte 
in eluent A injected by the integrated syringe pump and using Analyst® Software in 
Quantitative Optimization mode. The three resulting transitions per analyte and 
respective settings are given in Table 2.1. Cross-talk was not observed. As shown in 
Fig. 3.9, not only the parent and product ion masses are important for selective and 
sensitive detection and quantification, but also the analytes-specific instrument settings. 
Fig. 3.9 shows chromatograms of MRM transition 150 -> 77 with parameter settings 
optimized for synephrine (upper part) and for cathinone (lower part). Both 150 -> 77 
transitions have nearly the same collision cell energy, but differ in their declustering and 
entrance potentials. Being located before the collision cell, both potentials are analyte-
specific and not fragment-specific. Thus, choosing analyte-specific settings for the MRM 
transitions was critical for the sensitivity of the assay. Having quite similar mass 
spectrometric properties, sufficient chromatographic separation of the diastereomer 
pairs ephedrine/pseudoephedrine, methylephedrine/methylpseudoephedrine, and 
norephedrine/norpseudoephedrine was necessary for their differentiation. This could be 
achieved in less than 10 min using an SCX separation column and the described 
chromatographic conditions.  
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Fig. 3.9. Chromatograms of MRM transition 150 -> 77 with parameter settings optimized for synephrine 
(SY, upper part) and for cathinone (CA, lower part) using the given declustering potential (DP), entrance 
potential (ENP), collision cell entrance potential (CEP), and collision energy (CE).  
 
For illustration of the detection and identification procedure, smoothed, normalized, and 
merged MRM chromatograms of all target transitions of a LQC sample after SPE are 
shown Fig. 3.10. The peaks were sufficiently separated even in the highest calibrator. 
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Fig. 3.10. Smoothed, normalized, and merged MRM chromatograms of all target transitions of an extract 
of a LQC sample containing 10 ng/ml synephrine (SY, oxedrine), norephedrine (NE), 
norpseudoephedrine (NPE, cathine), ephedrine (EP), pseudoephedrine (PEP), cathinone (CA), mescaline 
(MES), methcathinone (MC), methylephedrine (ME), methylpseudoephedrine (MPE), 
norephedrine-d3 (NE-d3), ephedrine-d3 (EP-d3), and mescaline-d9 (MES-d9). 
 
3.3.3 Assay Validation 
The described procedure was validated according to internationally accepted 
recommendations.137,140,153,154 The validation data are summarized in Tables 3.2 and 
3.3. As exemplified in Fig. 3.11 (left), no interfering peaks were observed in the extracts 
of the different blank plasma samples. Interferences with common drugs of abuse which 
might be expected to be taken in combination with the analytes were tested and could 
be excluded.  
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The assay was found to be selective for all tested compounds. A weighted second-order 
model was also evaluated to check for a curvature in the data. For all analytes, a linear 
weighted (1/c2) least squares model was found to be the best and therefore used for 
calculation of calibration curves. It was linear from 10 to 1000 ng/ml of each compound. 
The coefficients of determination (R²) ranged from 0.9948 to 0.9996. 
The LLOQs corresponded to the lowest concentrations used for the calibration curves 
with a signal-to-noise ratio of at least 10. The validation data concerning extraction 
efficiency, matrix effects, and process efficiency are shown in Table 3.2 and those 
concerning accuracy and precision in Table 3.3. Accuracy data were determined and all 
lay within the acceptance interval of ±15% (±20% at the LLOQ) of the nominal values at 
all concentrations. Within-day (repeatability) and intermediate precision were also 
determined and lay within the required limits of 15% RSD (20% RSD at LLOQ), at all 
studied concentration levels.  
In extracts, the analytes were stable at low and high concentrations for a period of more 
than 24 h at 15° C. In the freeze/thaw and long-term stability experiments, the ratio of 
means (stability vs. control samples) were within 90-110%, whereas the 90% CIs for 
stability samples were within 80-120% of the respective control means, such fulfilling 
the acceptance criteria for all analytes at both concentrations. 
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3.3.4 Proof of Applicability 
Applicability experiments were carried out using plasma samples taken from healthy 
volunteers one hour after application of common doses of Herba Ephedra, 
pseudoephedrine, or ephedrine. Fig. 3.12 shows smoothed, normalized, and merged 
MRM chromatograms of extracts of authentic plasma samples after ingestion of Herba 
Ephedra (part 1), of pseudoephedrine (part 2), and of ephedrine (part 3). After ingestion 
of Herba Ephedra the ephedrines norephedrine, norpseudoephedrine, ephedrine, 
pseudoephedrine, methylephedrine, and methylpseudoephedrine were detected, 
whereas after ingestion of pseudoephedrine or ephedrine, contained in cold 
medications, only the applied substances were detected. The quantitative results are 
summarized in Table 3.4. 
 
Table 3.4. Plasma concentrations (ng/ml) of norephedrine (NE), norpseudoephedrine (NPE), ephedrine 
(EP), pseudoephedrine (PEP), methylephedrine (ME), and methylpseudoephedrine (MPE) after 
administration of the given drugs (LLOQ: lower limit of quantification). 
Administered drug (dose) NE NPE EP PEP ME MPE 
Herba Ephedra < LLOQ 14.9 20.0 16.0 < LLOQ - 
Herba Ephedra < LLOQ 20.3 25.5 15.8 < LLOQ < LLOQ
Pseudoephedrine (30 mg) - - - 107 - - 
Pseudoephedrine (30 mg) - - - 114 - - 
Ephedrine (6.2 mg) - - 21.5 - - - 
Ephedrine (6.2 mg) - - 21.6 - - - 
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Fig. 3.12. Smoothed, normalized, and merged MRM chromatograms of all target transitions of extracts of 
authentic plasma samples after ingestion of Herba Ephedra (part 1), of pseudoephedrine (part 2), and of 
ephedrine (part 3) indicating norephedrine (NE), norpseudoephedrine (NPE, cathine), ephedrine (EP), 
pseudoephedrine (PEP), methylephedrine (ME), and/or methylpseudoephedrine (MPE), and the internal 
standards NE-d3, EP-d3, and MES-d9. 
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3.4 TOXIC ALKALOIDS 
A single stage MS and a tandem MS assay were developed for selective detection as 
well as for accurate and precise quantification of toxic alkaloids in human plasma and 
compared with respect to selectivity, linearity, accuracy, precision, and matrix effects. 
Both assays were validated according to international guidelines.137,140,153,154  
 
3.4.1 Extraction Procedure 
In early development stages of the presented assay, it was intended to extract the 
analytes either by the plasma mixed-mode SPE procedure described for herbal 
phenalkylamines,157 or by their standard liquid-liquid extraction (LLE) procedure.158-160 
While colchicine showed better extraction efficiency using LLE, all other studied 
analytes showed better results using SPE. Therefore, the SPE procedure was preferred 
over LLE for extraction of these analytes from plasma. As shown in Tables 3.5 and 3.6, 
the extraction efficiency values ranged from 10 to 90 %. For colchicine the extraction 
efficiency was relatively low, which can be explained by its chemical properties. 
Whereas the used mixed-mode SPE procedure is optimized for basic compounds, 
colchicine shows no basic properties. Nevertheless, the described extraction procedure 
was considered acceptable due reproducible extraction and the sufficient sensitivity 
even for this analyte. 
 
3.4.2 Detection and Quantification 
For single stage MS, the APCI source was found to be more sensitive than the 
corresponding ESI source in preliminary experiments. In case of tandem MS coupled 
with the Turbo V® Source, the ESI mode was preferred over the APCI mode, because it 
was found to be more sensitive. Consequently, the different apparatus were compared 
using the respective most sensitive ionization mode. 
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In single stage MS, the presence of the analytes was screened for in the full scan mode 
by mass chromatography in the MSD 1 trace of the same run with the above given 
parameters. The following ions were used for screening (m/z, in order of appearance in 
the chromatogram): 191, 177, 180 (IS), 163, 128, 304, 293 (IS), 276, 290, 400, 298 (IS), 
and 646. Positive peaks in the recorded traces were identified by library search 
comparing the underlying APCI mass spectra with the reference spectra of our LC-MS 
library of drugs, poisons, pesticides and their metabolites created for the NIST98 search 
algorithm. The corresponding reference spectra recorded during this study are shown 
on the left side of Fig 3.13. In this Figure, the ions used for screening are underlined. 
In tandem MS, the presence of the drugs was successfully detected in the MRM mode 
using three MRM transitions for each substance. Transitions were selected and their 
settings were determined using a 1000 ng/ml solution of each analyte in eluent A 
injected by the integrated syringe pump and using Analyst® Software in Quantitative 
Optimization mode. The three resulting transitions per analyte and respective settings 
are given in Table 2.2. In the right part of Fig. 3.13, the product ion scan spectra, 
recorded during this study, are shown. The ions chosen as product ions are underlined. 
Cross-talk was not observed.  
For illustration of the detection and identification using the different apparatus, Fig. 3.14 
shows the respective chromatograms of a MED sample after SPE. Part A of Fig. 3.14 
shows smoothed and merged mass chromatograms of the ions 191, 177, 180 (IS), 163, 
128, 304, 293 (IS), 276, 290, 400, 298 (IS), and 646 using single stage MS, part B of 
Fig. 3.15 shows smoothed, and merged MRM chromatograms of all recorded transitions 
using tandem MS.  
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Fig. 3.13. Mass spectra of all studied analytes recorded in the full scan mode using single stage APCI MS 
(left), and corresponding product ion spectra recorded in the product ion scan mode using tandem ESI 
MS (right). 
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For quantification using single stage MS, SIM mode was used at 100 and 200 V 
fragmentor voltage with different gain values. For the quantification process, the 
analytes were divided into two different groups according to their expected 
concentration ranges and each group was assigned to one of three separately recorded 
traces with specific gain values as given in Table 2.2. 
For quantification using tandem MS, MRM mode was used. One of the three transitions 
of each substance was used for quantification. This target transition is marked with an 
(t) in Table 2.3. 
The peak area ratios of the target ions or the target transition of the drugs vs. those of 
the corresponding IS were compared with weighted least squares (1/c2) calibration 
curves in which the peak area ratios (analytes vs. IS) of the calibration standards were 
plotted versus their concentrations. The different IS were assigned to the different 
analytes as shown in tables 3.7 and 3.8. The Structures of the IS used for quantification 
are depicted in Fig. 3.14. 
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O
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Cotinine-d3Benzoylecgonine-d3 Trimipramine-d3  
Fig. 3.14. Chemical structures of the IS used for quantification. 
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3.4 Toxic Alkaloids 75 
 
 
 
Fig. 3.15. Smoothed and merged chromatograms of the ions 191, 177, 180 (IS), 163, 128, 304, 293 (IS), 
276, 290, 400, 298 (IS), and 646, recorded in the full scan mode, of a MED sample containing cytisine 
(peak 1), nicotine (2), cotinine-d3 (3), cotinine (4), coniine (5), scopolamine (6), benzoylecgonine-d3 (7), 
physostigmine (8), atropine (9), colchicine (10), trimipramine-d3 (11), and aconitine (12) after SPE using 
the single stage MS (A). Smoothed and merged MRM chromatograms of all recorded transitions of same 
MED sample after SPE using the tandem MS (B). 
3.4 Toxic Alkaloids 75 
 
 
 
Fig. 3.15. Smoothed and merged chromatograms of the ions 191, 177, 180 (IS), 163, 128, 304, 293 (IS), 
276, 290, 400, 298 (IS), and 646, recorded in the full scan mode, of a MED sample containing cytisine 
(peak 1), nicotine (2), cotinine-d3 (3), cotinine (4), coniine (5), scopolamine (6), benzoylecgonine-d3 (7), 
physostigmine (8), atropine (9), colchicine (10), trimipramine-d3 (11), and aconitine (12) after SPE using 
the single stage MS (A). Smoothed and merged MRM chromatograms of all recorded transitions of same 
MED sample after SPE using the tandem MS (B). 
3.4 Toxic Alkaloids 75 
 
 
 
Fig. 3.15. Smoothed and merged chromatograms of the ions 191, 177, 180 (IS), 163, 128, 304, 293 (IS), 
276, 290, 400, 298 (IS), and 646, recorded in the full scan mode, of a MED sample containing cytisine 
(peak 1), nicotine (2), cotinine-d3 (3), cotinine (4), coniine (5), scopolamine (6), benzoylecgonine-d3 (7), 
physostigmine (8), atropine (9), colchicine (10), trimipramine-d3 (11), and aconitine (12) after SPE using 
the single stage MS (A). Smoothed and merged MRM chromatograms of all recorded transitions of same 
MED sample after SPE using the tandem MS (B). 
3.4 Toxic Alkaloids 75 
 
 
 
Fig. 3.15. Smoothed and merged chromatograms of the ions 191, 177, 180 (IS), 163, 128, 304, 293 (IS), 
276, 290, 400, 298 (IS), and 646, recorded in the full scan mode, of a MED sample containing cytisine 
(peak 1), nicotine (2), cotinine-d3 (3), cotinine (4), coniine (5), scopolamine (6), benzoylecgonine-d3 (7), 
physostigmine (8), atropine (9), colchicine (10), trimipramine-d3 (11), and aconitine (12) after SPE using 
the single stage MS (A). Smoothed and merged MRM chromatograms of all recorded transitions of same 
MED sample after SPE using the tandem MS (B). 
76 3 Results and Discussion 
 
 
3.4.3 Assay Validation 
The described procedures were validated according to internationally accepted 
recommendations.137,140,153,154 The validation data are summarized in Tables 3.5-3.8. 
The assay was found to be selective for all tested compounds using either single stage 
MS or tandem MS. No interfering peaks were observed in the extracts of the different 
blank plasma samples using both detectors. When using the APCI mode, the tested IS 
nicotine-d4 showed a loss of 4 atomic mass units most probably due to aromatization of 
the pyrrolidine ring. The resulting fragment ion m/z 163 was isobaric to the protonated 
molecular ion of nicotine and hence interfered with the quantification of the latter. 
Therefore, nicotine-d4 could not be used as IS.  
As shown in Tables 3.5 and 3.6, no relevant matrix effects were observed for both types 
of ionization. The highest matrix effect was observed for physostigmine in the APCI 
mode and for scopolamine in the ESI mode, but considered acceptable due to good 
reproducibility. 
In linearity experiments, a weighted second-order model was also evaluated to check 
for a curvature in the data. For all analytes, a linear weighted (1/c2) least squares model 
was found to be the best and therefore used for calculation of calibration curves. Using 
single stage MS, the assay was linear from 50 to 1000 ng/ml for coniine, cotinine, 
cytisine, and nicotine, as well as from 5 ng/ml to 100 ng/ml for aconitine, atropine, 
colchicine, physostigmine, and scopolamine, respectively. The coefficients of 
determination (R²) ranged from 0.9894 to 0.9997. Using tandem MS, the assay was 
linear from 1 to 1000 ng/ml for coniine, cotinine, cytisine, and nicotine, as well as from 
0.1 ng/ml to 100 ng/ml for aconitine, atropine, colchicine, physostigmine, and 
scopolamine, respectively. The coefficients of determination (R²) ranged from 0.9912 to 
0.9994. The linearity was comparable either using single stage MS or tandem MS. In 
both assays, the worst coefficient of determination was found for nicotine, most 
probably due to its volatility, whereas the best results were found for cotinine, probably 
due to the use of its deuterated analogue as IS. 
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The LLOQs were fixed to the lowest concentrations used for the calibration curves with 
a signal-to-noise ratio of at least 10. All LOD values were lower or at least equal to half 
of those of the corresponding LLOQ, either using single stage MS or tandem MS. 
The validation data for both apparatus concerning extraction efficiency, matrix effects, 
and process efficiency are shown in Table 3.5 (single stage MS), and 3.6 (tandem MS) 
as well as those concerning accuracy and precision in Table 3.7 (single stage MS) and 
3.8 (tandem MS). Accuracy data lay within the acceptance interval of ±15% of the 
nominal values at all concentrations with the exception of those of nicotine most 
probably due to its volatility. Using nicotine-d4 as internal standard would probably solve 
these problems, but as mentioned above, this was not possible. Within-day 
(repeatability) and intermediate precision lay within the required limits of 15% RSD for 
both apparatus at all studied concentration levels.  
In extracts, the analytes were stable at low and high concentrations for a period of more 
than 24 h. In the freeze/thaw and long-term stability experiments, the ratio of means 
(stability vs. control samples) were within 90-110%, whereas the 90% CIs for stability 
samples were within 80-120% of the respective control means, thus fulfilling the 
acceptance criteria for all analytes at both concentrations. 
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80 3 Results and Discussion 
 
 
3.4.4 Proof of Applicability 
Applicability experiments were carried out using plasma samples from poisoning cases 
sent to our laboratory for toxicological analysis. Patient one accidentally ingested leaves 
of Colchicum autumnale (Meadow saffron) containing colchicine due to a mix-up with 
the vegetable Allium ursinum, known as Ramsons. In the upper part of Fig 3.16, the 
corresponding ion fragmentogram with the given ions of the plasma sample extract after 
SPE using LC-MS (A), as well as the MRM chromatograms with the given transitions 
using LC-MS/MS (B) are shown. Using single stage MS, a toxic concentration of 24 
ng/ml of colchicine was determined and using tandem MS 25 ng/ml. 
Patient two abused Datura stramonium containing atropine and scopolamine. In the 
lower part of Fig 3.16 the corresponding ion fragmentogram with the given ions of the 
plasma sample extract after SPE using LC-MS (C), as well as the MRM chromatograms 
with the given transitions using LC-MS/MS (D) are shown. Using single stage MS, a 
therapeutic concentration of 6.4 ng/ml of atropine, a toxic concentration of 5.6 ng/ml of 
scopolamine, and a common smoker’s concentration of 321 ng/ml of cotinine were 
determined and using tandem MS, 6.1 ng/ml of atropine, 5.9 ng/ml of scopolamine and 
319 ng/ml of cotinine. 
 
3.4.5 Comparison of Methods 
In all validation experiments of the two procedures, the identical plasma extracts were 
used. Therefore a comparison was possible of both apparatus operated in the 
respective most sensitive ionization mode. Both assays (single stage as well as tandem 
MS) were selective for the tested compounds. Comparing the spectra shown in 
Fig. 3.13, it can be seen that in tandem MS the identification power was higher due to 
the higher fragmentation of the precursor ions. Monitoring the transitions allowed limits 
of detection of about ten times lower in tandem MS than in single stage MS. As shown 
in Figs. 3.15 and 3.16, tandem MS yielded better signal-to-noise ratios in the identical 
extracts. In contrast to that advantage of tandem MS, the accuracy and precision data 
for both apparatus were comparable. No relevant matrix effects were observed in both 
assays. 
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Fig. 3.16. Smoothed, normalized and merged chromatograms with the given ions of a plasma extract 
after SPE indicating a toxic concentration of 24 ng/ml of colchicine (peak 10) determined using single 
stage MS (A). Smoothed, normalized and merged chromatograms of the given transitions of the same 
extract indicating a toxic concentration of 25 ng/ml of colchicine (peak 10) determined using tandem MS 
(B). Smoothed, normalized and merged chromatograms with the given ions of a plasma extract after SPE 
indicating a therapeutic concentration of 6.4 ng/ml of atropine (peak 9), a toxic concentration of 5.6 ng/ml 
of scopolamine (peak 6), and a common smoker’s concentration of 321 ng/ml of cotinine (peak 4) 
determined using single stage MS (C). Smoothed, normalized and merged chromatograms of the given 
transitions of the same extract indicating a therapeutic concentration of 6.1 ng/ml of atropine (peak 9), a 
toxic concentration of 5.9 ng/ml of scopolamine (peak 6), and a common smoker’s concentration of 319 
ng/ml of cotinine (peak 4) determined using tandem MS (D). The peak numbering of the IS is according to 
that of Fig. 3.15.  
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4 CONCLUSIONS 
The presented GC-MS procedures for the detection of laxatives allowed the 
identification and differentiation of stimulant laxatives and/or their metabolites in urine 
after ingestion of therapeutic doses. Therefore, this screening can be used for 
confirmation of an intake of these drugs during diagnosis or differential diagnosis of 
various intestinal disorders. Furthermore, introducing enzymatic cleavage of conjugates 
allowed to integrate successfully the described method into the previously described 
screening procedures for simultaneous detection of other drugs like first generation 
anticoagulants,71 ACE inhibitors and angiotensin II receptor antagonists,70 
dihydropyridine calcium channel blockers,72 diuretics,142,143 and NSAIDs.73  
 
The study covering the nutmeg ingredients showed that alkenebenzene derivatives 
elemicin, myristicin and safrole contained in nutmeg were extensively metabolized by 
rats and humans. However, these metabolites are not amphetamine derivatives as 
described in the 1970ies. For monitoring a nutmeg abuse or intoxication, the toxicologist 
should screen for the above-mentioned target analytes, particularly by the described 
STA.79-84 
 
The LC-MS and LC-MS/MS assays presented here for separation, detection and 
quantification of psychoactive herbal phenalkylamines of interest and methcathinone as 
well as toxic alkaloids of interest in plasma are the first validated multi-analyte 
procedures for such substances. All procedures have proven to be selective, linear, 
accurate and precise for all studied drugs with the exception of nicotine. As expected, 
the tandem MS is more selective and sensitive than the single stage MS. The accuracy 
and precision data for both apparatus were comparable. In case of poisoning, both 
apparatus can be used for detection and quantification. Only if low concentration must 
be monitored tandem MS is needed due to its higher sensitivity.  
 
All presented assays have also proven to be applicable for clinical and forensic 
toxicological tasks. 
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5 SUMMARY 
In the presented thesis, procedures are described for screening for, identification and/or 
validated quantification of herbal drugs in blood or urine using GC-MS, LC-MS or LC-
MS/MS. They are needed in in clinical and forensic toxicology, because poisonings with 
plants or plant ingredients as well as their abuse are widespread. The aims of such an 
abuse are stimulation, hallucinations, or even for weight loss or habitual use. In both 
cases, toxicological analysis is the prerequisite for reliable diagnosis, prognosis and 
monitoring. The following drugs or drugs classes were included in this method 
development: laxatives, ingredients of nutmeg, herbal phenalkylamines, and toxic 
alkaloids. 
For detection of the acidic laxatives bisacodyldiphenol, phenolphthalein, and rhein in 
urine, extractive methylation was used. The analytes were derivatized and 
simultaneously extracted using methyl iodide in toluene and the phase transfer catalyst 
tetrahexylammonium hydrogen sulfate. The phase transfer catalyst was removed from 
the organic phase by solid phase extraction. The extracts were analyzed by GC-MS. 
The developed method allowed the identification and differentiation of stimulant 
laxatives and/or their metabolites in urine after ingestion of therapeutic doses.161 
In the study covering the nutmeg ingredients, metabolism and toxicological analysis in 
urine of elemicin, myristicin, and safrole were investigated. The qualitative metabolism 
was studied in Wistar rats, that were administered a high dose of the corresponding 
nutmeg ingredient. The metabolites were identified by GC-MS. The study showed that 
the nutmeg ingredients were extensively metabolized, and that the parent compounds 
were not detectable in urine. For toxicological analysis, an established method including 
acid hydrolysis, liquid-liquid extraction and microwave-assisted acetylation was used. 
The derivatized metabolites were separated and detected using GC-MS in the full scan 
mode. Using this procedure, a nutmeg abuse or intoxication can be monitored via 
detection of the metabolites.162 
Detection and validated quantification of herbal phenalkylamines ephedrine, 
pseudoephedrine, norephedrine, norpseudoephedrine, methylephedrine, 
methylpseudoephedrine, cathinone, mescaline, synephrine (oxedrine), and 
methcathinone in human plasma were based on a standard solid-phase extraction 
procedure using mixed-mode SPE columns. The analytes were seperated using a liquid 
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chromatography with a strong cation exchange seperation column as stationary phase, 
and a gradient elution with 5 mM ammonium formate buffer/acetonitril as mobile phase. 
The analytes were detected with an LC-ESI-MS/MS operated in the MRM mode. The 
method allowed the detection of ephedrines after ingestion of therapeutic doses, 
selective, linear, accurate and precise quantification, as well as the differentiation of an 
herbal drugs abuse from ingestion of cold remedies.157 
Detection and validated quantification of the toxic alkaloids aconitine, atropine, 
colchicine, coniine, cotinine, cytisine, nicotine, physostigmine, scopolamine in human 
plasma were based on the identical extraction procedure used for the extraction of the 
herbal phenalkylamines. The analytes were seperated using a liquid chromatography 
with a C8 base select seperation column as stationary phase, and a gradient elution 
with 50 mM ammonium formate buffer/acetonitril as mobile phase. The analytes were 
detected either with an LC-APCI-MS operated in full scan and SIM mode or an LC-ESI-
MS/MS operated in the MRM mode. In this study, the use of LC-APCI-MS vs LC-ESI-
MS/MS was directly compared. As expected, the tandem MS was more selective and 
sensitive than the single stage MS. The accuracy and precision data for both apparatus 
were comparable. In case of poisoning, both apparatus can be used for detection and 
quantification. Only if low concentration must be monitored tandem MS is needed due to 
its higher sensitivity.163 
 
In summary, all presented methods have proven to be reliable and accurate and are 
now a valuable tool in clinical and forensic toxicology. 
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Liquid chromatography-tandem mass spectrometry 
7 ABBREVIATIONS 
ACR Above calibraton range 
ANOVA Analysis of Variance 
APCI Atmospheric pressure chemical ionization 
CE Collision energy 
CEP Collision cell entrance potential 
CNS Central nervous system 
CXP Collision cell exit potential 
DP Declustering potential 
EI electron ionization 
ENP Entrance potential 
ESI Electrospray ionization 
FT Forensic toxicology 
GC-MS Gas chromatography-mass spectrometry 
HPLC High performance liquid chromatography 
IS Internal standard 
LC-MS Liquid chromatography-mass spectrometry 
LC-MS/MS 
LLOQ Lower limit of quantification 
LOD Limit of detection 
LQC Low quality control 
m/z Mass to charge ratio 
MDA 3,4-Methylendioxyamphetamine 
MMDA 3,4-Methylendioxy-5-methoxyamphetamine 
MRM Multiple reaction monitoring 
MS Mass spectrometry 
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NMR nuclear megnetic resonance 
PMA 4´-Methoxyamphetamine 
QC Quality control 
RSD Relative standard deviation 
S/N Signal to noise ratio 
SCX Strong Cation exchange 
SIM Selected-ion monitoring 
SPE Solid-phase extraction 
STA Systematic toxicological analysis 
TDM Therapeutic drug monitoring 
THA Tetrahexylammonium 
THC Tetrahydrocannabinol 
TLC Thin layer chromatography 
TMA 3,4,5-Trimethoxyamphetamine 
UV Ultraviolett 
102 7 Abbreviations 
 
 
 
NMR nuclear megnetic resonance 
PMA 4´-Methoxyamphetamine 
QC Quality control 
RSD Relative standard deviation 
S/N Signal to noise ratio 
SCX Strong Cation exchange 
SIM Selected-ion monitoring 
SPE Solid-phase extraction 
STA Systematic toxicological analysis 
TDM Therapeutic drug monitoring 
THA Tetrahexylammonium 
THC Tetrahydrocannabinol 
TLC Thin layer chromatography 
TMA 3,4,5-Trimethoxyamphetamine 
UV Ultraviolett 
102 7 Abbreviations 
 
 
 
NMR nuclear megnetic resonance 
PMA 4´-Methoxyamphetamine 
QC Quality control 
RSD Relative standard deviation 
S/N Signal to noise ratio 
SCX Strong Cation exchange 
SIM Selected-ion monitoring 
SPE Solid-phase extraction 
STA Systematic toxicological analysis 
TDM Therapeutic drug monitoring 
THA Tetrahexylammonium 
THC Tetrahydrocannabinol 
TLC Thin layer chromatography 
TMA 3,4,5-Trimethoxyamphetamine 
UV Ultraviolett 
102 7 Abbreviations 
 
 
 
NMR nuclear megnetic resonance 
PMA 4´-Methoxyamphetamine 
QC Quality control 
RSD Relative standard deviation 
S/N Signal to noise ratio 
SCX Strong Cation exchange 
SIM Selected-ion monitoring 
SPE Solid-phase extraction 
STA Systematic toxicological analysis 
TDM Therapeutic drug monitoring 
THA Tetrahexylammonium 
THC Tetrahydrocannabinol 
TLC Thin layer chromatography 
TMA 3,4,5-Trimethoxyamphetamine 
UV Ultraviolett 
 103 
 
 
 
8 ZUSAMMENFASSUNG 
Die vorliegende Dissertation beschreibt Methoden zur Suchanalyse, Identifizierung 
und/oder validierten Quantifizierung von pflanzlichen Arzneistoffen in Blut oder Urin 
unter der Verwendung GC-MS, LC-MS oder LC-MS/MS. Diese Methoden werden 
sowohl in der klinischen wie auch der forensischen Toxikologie aufgrund der 
Verbreitung von Pflanzenvergiftungen bzw. Vergiftungen mit Pflanzenwirkstoffen sowie 
deren Missbrauch benötigt. Die Beweggründe eines solchen Missbrauchs sind 
Stimulation, Halluzinationen, aber auch Gewichtsverlust oder Gewöhnung. Sowohl zur 
Diagnose eines Missbrauchs als auch einer Vergiftung sind toxikologische Analysen 
eine Grundvorrausetzung zur zuverlässigen Diagnose, Prognose und Überwachung. 
Die folgenden Stoffe oder Stoffklassen wurden bei dieser Methodenentwicklung 
berücksichtigt: Laxanzien, Inhaltsstoffe der Muskatnuss, pflanzliche Phenalkylamine 
und giftige Alkaloide.  
Zum Nachweis der sauren Laxanzien Bisacodyldiphenol, Phenolphthalein und Rhein in 
Urin wurde die Extraktive Methylierung eingesetzt. Hierbei werden die Analyten durch 
Methyliodid in Toluol und den Phasentransferkatalysator Tetrahexylammonium-
hydrogensulfat derivatisiert und gleichzeitig extrahiert. Der Phasentransferkatalysator 
wurde aus der organischen Phase mittels Festphasenextraktion entfernt. Die 
resultierenden Extrakte wurden unter Zuhilfenahme von GC-MS analysiert. Die im 
Rahmen dieser Dissertation entwickelte Methode erlaubt die Identifizierung und 
Differenzierung der stimmulierenden Laxanzien und/oder deren Metaboliten nach 
Einnahme einer therapeutischen Dosis.161 
Des Weiteren wurde der Metabolismus sowie der toxikologische Nachweis von 
Elemicin, Myristicin und Safrol, welche Inhaltsstoffe der Muskatnuss sind, untersucht. 
Die qualitativen Metabolismusuntersuchungen erfolgten an Wistar Ratten, denen eine 
hohe Dosis der jeweiligen Substanz verabreicht wurde. Die Metaboliten wurden mittels 
GC-MS identifiziert. Die Untersuchungen zeigten, dass die Inhaltsstoffe der Muskatnuss 
aufgrund der ausgeprägten Metabolisierung im Urin nicht nachweisbar waren. Als 
toxikologisches Nachweisverfahren diente in diesem Fall eine etablierte Methode 
basierend auf einer sauren Hydrolyse zur Konjugatspaltung, Flüssig-Flüssig-Extraktion 
und Mikrowellenunterstützter Acetylierung. Die derivatisierten Metaboliten wurden 
mittels GC-MS im full-scan Modus aufgetrennt und detektiert. Diese Methode erlaubt 
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den Nachweis einer Vergiftung sowie Nachweis eines Missbrauchs von Muskatnuss 
durch Detektion der Metaboliten der Muskatnussinhaltsstoffe.162 
Die Detektion sowie die validierte Quantifizierung der pflanzlichen Phenalkylamine 
Ephedrin, Pseudoephedrin, Norephedrin, Norpseudoephedrin, Methylephedrin, 
Methylpseudoephedrin, Cathinon, Mescalin, Synephrin (Oxedrin) und Methcathinon im 
Blut basierte auf einer standardmäßig verwendeten Festphasenextraktion unter 
Zuhilfenahme von Mixed-mode Festphasensäulen. Die Analyten wurden mittels 
Flüssigchromatographie mit einer starken Kationentauscher-Säule als stationäre Phase 
und einem Gradientengemisch aus 5 mM Ammoniumformiatpuffer/Acetonitril getrennt. 
Zur Detektion diente ein LC-ESI-MS/MS, welches im MRM Modus betrieben wurde. Die 
Methode erlaubt die Detektion der Ephedrine nach Einnahme therapeutischer 
Dosierungen, die selektive, lineare, richtige und präzise Quantifizierung der genannten 
Substanzen sowie die Unterscheidung eines Missbrauchs von Pflanzen von der 
Einahme eines Erkältungsmittels.157 
Die Detektion sowie die validierte Quantifizierung der giftigen Alkaloide Aconitin, 
Atropin, Colchicin, Coniin, Cotinin, Cytisin, Nicotin, Physostigmin und Scopolamine im 
Blut basierten auf der identischen Extraktion wie für die pflanzlichen Phenalkylamine. 
Die Analyten wurden mittels Flüssigchromatographie mit einer C8 base select-Säule als 
stationäre Phase und einem Gradientengemisch aus 50 mM Ammoniumformiat-
puffer/Acetonitril getrennt. Zur Detektion diente entweder ein LC-APCI-MS, welches im 
full-scan bzw. im SIM Modus betrieben wurde, oder ein LC-ESI-MS/MS, welches im 
MRM Modus betrieben wurde. Im Rahmen dieser Untersuchung wurden der 
verwendete LC-APCI-MS sowie der LC-ESI-MS/MS direkt miteinander verglichen. Wie 
zu erwarten war der Tandem MS selektiver und empfindlicher als der Single Stage MS. 
Die Richtigkeits und Präzisionswerte hingegen waren vergleichbar. Zum Nachweis und 
zur Quantifizierung einer Vergiftung sind beide Geräte geeignet. Wenn allerdings 
niedrigste Konzentrationen der Stoffe überwacht werden müssen, bedarf es der 
Benutzung eines Tandem MS aufgrund dessen höherer Sensitivität.163 
Zusammenfassend lässt sich sagen, daß alle hier präsentierten Methoden zuverlässig 
und genau sind. Diese Methoden sind ein wertvolles Werkzeug sowohl in der klinischen 
als auch der forensichen Toxikologie. 
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Zuhilfenahme von Mixed-mode Festphasensäulen. Die Analyten wurden mittels 
Flüssigchromatographie mit einer starken Kationentauscher-Säule als stationäre Phase 
und einem Gradientengemisch aus 5 mM Ammoniumformiatpuffer/Acetonitril getrennt. 
Zur Detektion diente ein LC-ESI-MS/MS, welches im MRM Modus betrieben wurde. Die 
Methode erlaubt die Detektion der Ephedrine nach Einnahme therapeutischer 
Dosierungen, die selektive, lineare, richtige und präzise Quantifizierung der genannten 
Substanzen sowie die Unterscheidung eines Missbrauchs von Pflanzen von der 
Einahme eines Erkältungsmittels.157 
Die Detektion sowie die validierte Quantifizierung der giftigen Alkaloide Aconitin, 
Atropin, Colchicin, Coniin, Cotinin, Cytisin, Nicotin, Physostigmin und Scopolamine im 
Blut basierten auf der identischen Extraktion wie für die pflanzlichen Phenalkylamine. 
Die Analyten wurden mittels Flüssigchromatographie mit einer C8 base select-Säule als 
stationäre Phase und einem Gradientengemisch aus 50 mM Ammoniumformiat-
puffer/Acetonitril getrennt. Zur Detektion diente entweder ein LC-APCI-MS, welches im 
full-scan bzw. im SIM Modus betrieben wurde, oder ein LC-ESI-MS/MS, welches im 
MRM Modus betrieben wurde. Im Rahmen dieser Untersuchung wurden der 
verwendete LC-APCI-MS sowie der LC-ESI-MS/MS direkt miteinander verglichen. Wie 
zu erwarten war der Tandem MS selektiver und empfindlicher als der Single Stage MS. 
Die Richtigkeits und Präzisionswerte hingegen waren vergleichbar. Zum Nachweis und 
zur Quantifizierung einer Vergiftung sind beide Geräte geeignet. Wenn allerdings 
niedrigste Konzentrationen der Stoffe überwacht werden müssen, bedarf es der 
Benutzung eines Tandem MS aufgrund dessen höherer Sensitivität.163 
Zusammenfassend lässt sich sagen, daß alle hier präsentierten Methoden zuverlässig 
und genau sind. Diese Methoden sind ein wertvolles Werkzeug sowohl in der klinischen 
als auch der forensichen Toxikologie. 
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